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SUMMARY 
The severe and acute respiratory syndrome (SARS) outbreak threatened the 
world in year 2003. SARS Coronavirus (SARS-CoV) was identified as the 
causative agent of this disease. SARS-CoV has evolved several novel proteins, 
which share no similarity with known proteins. In this study, SARS-CoV accessory 
proteins ORF9b and ORF6 were characterized. ORF9b was illustrated to undergo 
translation via ribosomal leaky scanning after the introduction of mutations to the 
context of the translation initiation sites.  ORF9b was also demonstrated to 
facilitate virus assembly and release when it was co-expressed with structural 
protein M. ORF9b may carry out its functions via interaction with structural 
proteins E and M. ORF9b is incorporated into virion like particles as structural 
protein at presence of other structural proteins including M.  
H1299 cells with stable ORF6 expression, and Infectious Bronchitis Virus 
(IBV) with stable SARS-CoV ORF6 expression, were engineered. The gene profile 
in H1299-S6 was examined with microarray gene chip. ORF6 was shown to inhibit 
interferon production, and this inhibition may be caused by its interaction with 
IRF3. ORF6 doesn't prevent IRF3 phosphorylation, but prevents its entry into 
nucleus. ORF6 affects phosphorylation of STAT1, and was also shown to interfere 
with cell death. Microarray data also suggested that SARS-CoV ORF6 might 
interfere with other cell functions, like tissue morphology, molecular transport, 
nucleic acid metabolism and antigen presentation. Reverse genetic approach was 
used to generate recombinant Infectious Bronchitis Virus with foreign genes, and 
this method is a promising platform for gene delivery and vaccine development. 
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CHAPTER 1. LITERATURE REVIEW 
  2 
1.1 DISEASES PROVOKED BY CORONAVIRUSES 
In the year 2003, coronaviruses received worldwide attention during the 
severe and acute respiratory syndrome (SARS) outbreak . Coronaviruses belong to 
the family Coronaviridae, genus Coronavirus, and are large, enveloped, positive 
sense single-stranded RNA viruses. They occupy the largest genomes of all known 
RNA viruses, and possess unique transcription mechanisms (Lai and Cavanagh, 
1997; Lai and Holmes, 2001).  
Coronaviruses are known as a diverse group with a wide range of hosts 
from avian to mammalian species (Murray et al., 1992; Lai and Holmes, 2001). 
Coronavirus infection in fowls and livestock can result in severe economic losses, 
while human coronaviruses cause common cold, respiratory tract infection, and 
encephalitis.  
Coronaviruses were classified into three main groups based on serological 
analysis and antibody cross-reactivity tests (Table 1.1). Among these viruses, 
Transmissible gastroenteritis virus (TGEV), Mouse Hepatitis Virus (MHV) and 
Infectious Bronchitis Virus (IBV) have been widely studied in previous research. 
Table 1.2 shows the natural hosts and disease syndrome of coronaviruses. 
1.2 SARS-CORONAVIRUS 
SARS-Coronavirus (SARS-CoV) was identified as the pathogen of SARS (Drosten 
et al., 2003; Fouchier et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003b). SARS 
is the first new infectious disease of the 21
st
 century (WHO report, 2003).  The 
number of SARS patients worldwide totaled 8098, with 774 deaths in 32 countries. 
It almost paralyzed the global economy and had a profound impact on tourism, 
education and employment (WHO report, 2003). The mortality rate of SARS is 
  3 
approximately 10%, but it also depends on the age group. The mortality rate was 
found to be low in children but relatively high in the elderly population, with up to 
50% mortality rate (Stadler et al., 2003; Hon et al., 2003). 
  4 
Table 1.1 Coronavirus Species and Groups 
 
Group α 
     Subgroup α a 
 Porcine transmissible gastroenteritis 
coronavirus (TGEV) 
 Canine enteric coronavirus (CECoV) 
 Feline coronavirus (FCoV) 
     Subgroup α b 
 
 
Porcine epidemic diarrhea coronavirus (PEDV) 
 Human coronavirus 229E (HCoV) 
 Bat coronavirus 
Group β 
     Subgroup β a 
 Murine hepatitis coronavirus (MHV) 
 Human coronavirus OC43 (HCoV OC43) 
 Bovine coronavirus (BCoV) 
 Canine respiratory coronavirus (CRCoV) 
 Porcine haemagglutinating encephalomyelitis 
coronavirus (HEV) 
     Subgroup β b 
 SARS-coronavirus (SARS-CoV) 
Group γ 
 Infectious bronchitis coronavirus (IBV) 
 Turkey coronavirus (TCoV) 
 Goose coronavirus (GCoV) 
 Duck coronavirus (DCoV) 
 Pigeon coronavirus (PiCoV)  
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α HCoV229E Human X    
TGEV, 
PRCoV 
Pig X X   
CCoV Dog  X   
FECoV Cat  X X X 
FIPV Cat X X   
RbCoV Rabbit X X   
β HCoVOC43 Human X    
MHV Mouse X X X X 
SDAV Rat     
HEV Pig X X  X 
BCoV Cow X X   
γ IBV Chicken X  X  
TCoV Turkey X X   
 
 
HCoV-229E, human respiratory coronavirus; TGEV, Porcine transmissible 
gastroenteritis virus; PRCoV, porcine respiratory coronavirus; CCoV, canine 
coronavirus; FECoV, feline enteric coronavirus; FIPV, feline infectious peritonitis 
virus; RbCoV, rabbit coronavirus; HCoV-OC43, human respiratory coronavirus; 
MHV, murine hepatitis virus; SDAV, sialodacryoadenitis virus; HEV, porcine 
hemagglutinating encephalomyelitis virus; BCoV, bovine coronavirus; IBV, avian 
infectious bronchitis virus; TCoV, turkey coronavirus.  
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 1.2.1 Virion morphology 
When viewed under electron microscopy, SARS-CoV possesses a corona-like 
morphology (Fig. 1.1a) with pleomorphic spherical particles of approximately 
100nM in diameter (Marra et al., 2003; Rota et al., 2003). The viral envelope is 
noticeably bordered and evenly dispersed with 20nM long projectors. It is 
composed of a lipid bilayer, associated with Membrane (M) and Envelope (E) 
proteins, and is also incorporated with Spike (S) proteins (Rota et al., 2003). The 
positive, single-stranded RNA genome is integrated with the Nucleocapsid (N) 
protein within the envelope (Fig. 1.1b). 
1.2.2 Classification of SARS-CoV 
SARS-CoV is classified under group 2b of coronaviruses based on the 
phylogenetic analysis in conserved regions (Snijder et al., 2003). The initial 
phylogenetic analysis of the predicted viral proteins, however, indicated that the 
SARS-CoV does not closely resemble any of the three groups of coronaviruses 
(Marra et al., 2003; Rota et al., 2003) (Fig. 1.2a). Thereafter, through the usage of 
rooted phylogenetic trees, the analysis of ORF1b, which is the most conserved 
region in the SARS-CoV genome, indicated that the SARS-CoV represents an early 
split-off from group 2 (Snijder et al., 2003) (Fig. 1.2b). The Rappuoli group also 
arrived at this similar conclusion, using a different approach by studying less 
conserved proteins such as the papain-like protease (PLpro), S, M and N proteins 
(Eickmann et al., 2003; Stadler et al., 2003). The close relationship of SARS-CoV 
with group 2 coronaviruses is reinforced by the observation that 19 out of 20 
cysteine residues in the S1 domain of SARS-CoV S protein are conserved 
compared with the group 2 consensus sequence, but very much less conserved 
when compared to those from group 1 or 3. In the recent years, there has also been 
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growing evidence that show the close relation of SARS-CoV to group 2 
coronavirus. However, SARS-CoV does not encode the hemagglutinin esterase 
(HE), one of the conserved proteins in group 2 coronaviruses, so SARS-CoV has 
been grouped into group 2b together with some newly identified SARS-CoV-like 
viruses (Stadler et al., 2003). HE is a viral envelope protein that functions in viral 
attachment. 
  8 
 
 
  9 
Figure 1.1 Morphology of SARS coronavirus   
A. Electron micrograph of SARS-CoV. Single virus particle negatively stained 
with PTA (Proc Natl Acad Sci 57: 933–940). Magnification 192,000×. 
B. Schematic diagram of SARS-CoV Spike proteins (S: orange projections) are 
radiated evenly on the lipid bilayer envelope. Together with S protein, membrane 
(M: blue) and envelope (E: pink) protein are associated with the lipid bilayer 
envelope. Nucleocapsid protein (N) integrated with viral RNA genome inside the 
viral envelope. 
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1.2.3 Genome organization of SARS-CoV 
SARS-CoV contains a large RNA genome of 29,727 nucleotides, excluding 
its poly(A) tail (Rota et al., 2003; Marra et al., 2003). The genomic RNA begins 
with a leader sequence (nucleotides 1 to 72), which is followed by 192 nucleotides 
of untranslated region (UTR). Downstream of the 5' UTR is two overlapping open 
reading frames (ORFs), 1a and 1b, that occupy two-thirds of the genome and 
encode the two polyproteins 1a and 1ab (Marra et al., 2003; Stadler et al., 2003). 
The remaining part of the genome is covered by ORFs coding for other SARS-CoV 
proteins. The SARS-CoV genome contains 14 ORFs encoding non-structural 
proteins, structural proteins (S, E, M and N proteins) and accessory proteins (Marra 
et al., 2003). Of these ORFs, ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b and 9b do not share any 
homology with other coronaviruses (Marra et al., 2003; Rota et al., 2003; Ziebuhr, 
2004). The SARS-CoV genome ends with a 340 nucleotide UTR and a poly(A) tail. 
In the SARS-CoV genome and at the upstream region of most ORFs, there 
is a consensus sequence (5’-ACGAAAC-3’) that is considered to be a transcription-
regulatory sequence (TRS) (Marra et al., 2003; Thiel et al., 2003). The TRS of 
SARS-CoV was determined by the manual alignment of the upstream region of 
potential initiating methionine codons (Sawicki et al., 1998). Together with the 
leader sequence, the 5' and 3' UTR, TRS directs the transcription and translation of 
coronavirus (Lai and Cavanagh, 1997; Stadler et al., 2003). The SARS-CoV 
genome is summarized in Figure 1.3. 
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Figure 1.2 Phylogenetic analyses of Coronaviruses  
A. Unrooted phylogenetic tree (Marra. et. al., 2003). SARS-CoV is not grouped 
into three coronavirus groups when the sequenced are analyzed with unrooted 
phylogentic methods. 
B. Rooted phylogenetic tree (Snijder et. al., 2003). SARS-CoV is grouped into 
coronavirus group β when the sequenced are analyzed with rooted phylogentic 
methods. 
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Figure 1.3 Schematic representation of SARS-CoV genomic organization 
The SARS-CoV genome begins with the leader sequence, followed by ORF1a and 
ORF1b, which respectively encode polyproteins 1a and 1ab that will eventually be 
cleaved into 16 small, functional proteins. Relative regions encoding for SAR-CoV 
structural protein and accessory proteins are also present. Green colr represents 
non-structural proteins; yellow color represents structural proteins; blue color 
represents accessory proteins; red color represents translation regulatory 
sequences..  
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1.2.4 The life cycle of Coronavirus 
The life cycle of SARS-CoV is similar to that of other coronaviruses. Viral 
genome replication occurs exclusively in the cytoplasm, and the life cycle consists 
mainly of the following steps: virus attachment and entry, transcription, translation, 
virion assembly and release (Figure 1.4). 
1.2.4.1 Attachment, penetration and uncoating 
Coronavirus life cycle begins with the specific binding of the virion to the 
plasma membranes of target cells. The main determinant of cell tropism is likely to 
be the binding of the S protein to a specific receptor on the cell surface. Receptors 
have been identified for several coronaviruses. The known cellular receptors for 
coronaviruses are listed in Table 1.3. Aminopeptidase N (APN) serves as a receptor 
for antigenic group 1 coronavirus including TGEV, Human Coronavirus HCoV 
229E, Canine enteric coronavirus (CCoV) and Feline Infectious Peritonitis virus 
(FIPV) (Delmas et al., 1992; Tresnan et al., 1996; Yeager et al., 1992). APN is a 
cell-surface, zinc-binding protease, which contributes to the digestion of small 
peptides in respiratory and enteric epithelia. APN is also found to be present in 
human neural tissue (Lachance et al., 1998). The MHV receptor (mCEACAM1) is 
a member of the carcinoembryonic antigen (CEA) family, which are a group of 
proteins within the immunoglobulin (Ig) superfamily (Dveksler et al., 1993; 
Williams et al., 1991). 
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Figure 1.4 Life cycle of coronaviruses 
Coronavirus entry into the cell through membrane fusion is mediated by binding of 
the spike protein, followed by the subsequent activation of a fusion peptide in its 
S2 domain that mediates entry through cellular endocytic compartments. 
Following fusion with the endosomal compartment, the viral RNA genome is 
released into the cytoplasm, where replication takes place. ORF1a/1b is first 
translated by host translation machinery, through a ribosomal frame-shifting 
mechanism, to produce a single polyprotein. This polyprotein is then cleaved by 
virally encoded proteases into the individual proteins necessary for replication. 
Subgenomic RNA synthesis occurs from a discontinuous transcription strategy 
adopted by the virus, which joins leader RNA sequences encoded at the 5’-end of 
the genome to the body sequences of each subgenomic RNA to produce a nested 
set of subgenomic mRNAs. These different subgenomic negative strands thus act 
as templates for the synthesis of their respective subgenomic mRNA counterparts, 
which are then translated into viral proteins for the localization to their relevant 
compartments. Nucleocapsid protein and virus genomic RNA first assembles in 
the cytoplasm to form the helical nucleocapsid. The complex then buds through 
membranes between the ER and the Golgi apparatus to acquire its envelope. The 
Spike protein, Envelope proten, and Membrane protein are transported from ER to 
the budding compartment for the assembly of progeny virions in vesicles. The 
vesicles are then exported to the host cell surface where fusion of virion-containing 
vesicles with the plasma membrane occurs before their release into the exterior 
environment.
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Table 1.3 Coronavirus Receptors 
Group Virus species Receptor 
α   
 TGEV Porcine aminopeptidase N (pAPN) 
 PRCoV Porcine aminopeptidase N (pAPN) 
 FIPV Feline aminopeptidase N (fAPN) 
 FCoV Feline aminopeptidase N (fAPN) 
 CCoV Canine aminopeptidase N (cAPN) 
 HCoV-229E Human aminopeptidase N (hAPN) 
 HCoV-NL63 Angiotensin-converting enzyme 2 (ACE2) 
β   
 MHV Murine carcinoembryonic antigen-related  
adhesion molecules 1 (mCEACAM1) 
 BCoV 9-O-acetyl sialic acid 
 SARS-CoV Angiotensin-converting enzyme 2 (ACE2) 
CD209L (L-SIGN) 
γ   
 IBV α2,3-linked sialic acid 
 
 
  19 
Other group 2 coronaviruses use different receptors. The 9-O-acetyl sialic acid 
was identified as a cell attachment factor for Bovine coronavirus (BCoV) (Schultze 
et al., 1991). The angiotensin converting enzyme 2 (ACE2) was identified as the 
receptor of SARS-CoV (Li et al., 2003). ACE2 is a zinc-binding carboxypeptidase 
that is involved in the regulation of heart function. Human CD209L (also called L-
SIGN, or DC-DIGNR), a lectin family member, was found to act as a second 
receptor for SARS-CoV, but it has a much lower efficiency than compared with 
ACE2 (Jeffers et al., 2004). Recently, IBV was shown to preferentially recognize 
α2,3-linked sialic acid and this binding may be used by IBV for primary attachment 
to the cell surface (Winter et al., 2006). 
After the binding of an enveloped virus to its specific receptor, it enters the 
cell through the fusion of the viral lipid envelope with the plasma or endosomal 
membranes. IBV, MHV and BCoV exhibit a neutral or slightly alkaline optimal pH 
for the induction of cell to cell fusion (Li and Cavanagh, 1992; Payne and Storz, 
1988; Sturman et al., 1990; Weismiller et al., 1990). These viruses probably enter 
the cell by virus-cell fusion at the plasma membrane. MHV may also enter cells 
through the endosomal pathway (Krzystyniak and Dupuy, 1984; Mizzen et al., 
1985). The transmembrane domain of the S protein has been shown to induce 
conformation changes after binding to the receptor (Weismiller et al., 1990). The 
conformational change that separates S1 from the rest of the molecule, in turn, 
transmits a major change to S2. The coronavirus S2 domain contains two separate 
heptad repeats, HR1 and HR2, with a fusion peptide upstream of HR1 and the 
transmembrane domain immediately after HR2. The receptor-mediated 
conformational change in S1, and the subsequent dissociation of S1 from S2, 
initiates a rearrangement in the remaining S2 trimer. This rearrangement exposes a 
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fusion peptide that interacts with the host cellular membrane and brings together 
the two heptad repeats to form an antiparallel six-helix bundle. The result is the 
sufficient proximity of the viral and cellular membrane, which allows for the 
mixing of their lipid bilayers. The mechanism by which the virus uncoats and 
releases its genomic RNA into the cytoplasm is not clear yet.  
1.2.4.2 The discontinuous model of mRNA synthesis 
The coronavirus genomic RNA is transcribed into negative strand RNA, 
which directs the synthesis of full-length and subgenomic length mRNAs. In 
addition to the viral mRNAs, other RNA forms including full-length and 
subgenomic length negative strand RNAs, replicative form RNAs, were detected in 
TGEV, BCoV and MHV infected cells (Baric and Yount, 2000; den Boon et al., 
1996; Sawicki and Sawicki, 1990; Schaad and Baric, 1994; Sethna et al., 1989; 
Sethna et al., 1991b). The negative strand RNAs are complementary to the mRNAs, 
all containing a 5’ poly(U) tract and 3’ anti-leader sequence (Sethna and Hofmann, 
1991). During viral infection, synthesis of the negative-sense RNA peaks earlier 
and drops more rapidly than the positive-sense RNA (Sawicki and Sawicki, 1986). 
Coronavirus-infected cells contain 10-100 fold more positive-sense viral RNA than 
negative-sense (Perlman et al., 1986; Sawicki and Sawicki, 1986).  
Each of the 5’ most ORF in the mRNA is preceded by a TRS, which contains 
a highly conserved sequence (CS) that functions in the synthesis of the subgenomic 
mRNAs (Budzilowicz et al., 1985; Joo and Makino, 1992; Makino et al., 1991; 
Makino and Joo, 1993; Sethna et al., 1991b). The length and sequence of the CS 
varies depending on the particular coronavirus (5’-CUAAAC-3’ for TGEV; 5’-
UCUAAAC-3’ for MHV; 5’-CUUAACAA-3’ for IBV). Acquisition of the leader 
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sequence during mRNA synthesis appears to be TRS-dependent, and the leader to 
body joining is guided by a base-pairing interaction involving the leader and body 
TRS. 
    A discontinuous transcription model has been proposed as the mechanism 
for subgenomic RNAs generation  (Raman and Brian, 2005; Zhang et al., 2005; 
Sawichi 2005) (Fig. 1.5). Coronaviruses transcription follows a discontinuous 
mechanism and is directed by the 5' leader sequence, 5' UTR and 3' UTR (Raman 
and Brian, 2005; Zhang et al., 2005). One model is proposed for the discontinuous 
transcription mechanism of coronaviruses: the leader sequence serves as a primer 
for the synthesis of subgenomic mRNAs, and the full-length positive strand RNA is 
replicated into minus-strand templates, which would in turn be transcribed into 
subgenomic mRNAs. The subgenomic mRNAs cannot serve as templates for minus 
strand synthesis; only the genomic RNA is able to (Sawichi, 2005). 
Both viral and cellular proteins are required for viral RNA replication and 
transcription (Enjuanes et al., 2006). The virus specific RNA-dependent RNA 
polymerase (RdRp) nsp12 is responsible for the synthesis of negative-strand RNA 
from the genomic RNA and subsequent transcription of viral mRNA from the 
negative-strand template. Known cellular host factors involved in coronavirus 
RNA synthesis include the heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) 
(Shi and Lai, 2005), while the viral structural N protein is required for viral RNA 
synthesis (Hurst et al., 2010), and has also been discovered to possess RNA 
chaperone activity that may possibly play a role during template switch (Enjuanes 
et al., 2006; Mir and Panganiban, 2006). 
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Figure 1.5 Discontinuous transcription model of subgenomic RNA synthesis  
The genome is first translated into pp1a and pp1ab. Minus strands are synthesized 
by these replicase proteins. These minus strands are then used as templates for plus 
strand synthesis. Only the genomes are capable of serving as templates for minus 
strand synthesis because only they have a replication signal at their 5’ and 3’ ends. 
The subgenomic mRNA cannot serve as templates for minus strand synthesis 
because they lack the 5’ replication signal. After serving as templates for several 
rounds of plus strand synthesis, the minus strands are released from the 
replication/transcription complexes, which do not appear to be different for those 
making genomes compared with those making subgenomic mRNA. The minus 
strands are then subjected to degradation after their release. 
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1.2.4.3 Translation mechanism of SARS-CoV 
Most SARS-CoV proteins are translated by a cap-dependent translation 
mechanism. The leader sequence, the 5' terminus cap and the 3' end poly(A) tail 
present at each subgenomic mRNA can form a complex, which binds ribosome 
(Sachs et al., 1997). The cap has several important functions in RNA splicing, 
transport, stabilization, and translation. During translation initiation, the cap 
structure recruits the 40S ribosomal subunit to the. It may also transport the 40S 
subunit recruited by the  poly A tail to the 5′ end of the mRNA. The cap structure 
binds the eukaryotic initiation factor (eIF) eIF4F complex through the cap binding 
protein eIF4E. The ribosome scans through the genomic and subgenomic mRNAs 
and starts translation at the first AUG encountered. The optimal context for the 
recognition of AUG as an initiation codon is GCCRCCaugG (Kozak, 2002). The 
purine (R) at position -3 and the G at position +4 are highly conserved. When the 
first AUG codon occurs in a strong context, all or almost all ribosomes stop and 
initiate at that point. However, when AUG resides in a very weak context, lacking 
both R and G at -3 and +4 position respectively, leaky scanning occurs with some 
ribosomes initiating at that position while others continue scanning and initiate 
further downstream. 
Some SARS-CoV accessory proteins are translated from polycistronic 
mRNAs. The translation mechanism of these proteins is yet to be elucidated. For 
example, Hepta- and Octo-Uridine stretches are sole signals for programmed +1 
and -1 ribosomal frameshifting during translation of SARS-CoV ORF 3a variants 
(Wang et al., 2006). It is predicted that protein 3b is generated by an internal 
ribosomal entry mechanism. Similarly, it is predicted that proteins 7b and 9b are 
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generated by a leaky scanning mechanism (Snijder et al., 2003). Several different 
mechanisms are used by other coronaviruses for these polycistronic mRNAs. 
1.2.4.3.1 Ribosomal frameshifting within the polymerase gene 
 All of the coronavirus polymerase genes sequenced so far contains two large 
overlapping ORFs. It was demonstrated that translation of ORF 1b involved 
ribosomal frameshifting from ORF 1a, thus synthesizing a large polyprotein 
containing both 1a and 1b sequence. This mechanism has been shown to operate in 
gene 1 of MHV, HCoV-229E, IBV and TGEV as well (Bredenbeek et al., 1990; 
Brierley et al., 1987; Brierley et al., 1989; Brierley et al., 1990; Eleouet et al., 1995; 
Herold and Siddell, 1993; Somogyi et al., 1993). In all cases, the mechanism 
involves two essential elements: a heptanucleotide slippery sequence and a 
downstream, hairpin-type pseudoknot. The slippery site has the sequence 
UUUAAAC. The pseudoknots of IBV and MHV are similar, comprising two base-
paired regions stacked coaxially in a quasi-continuous manner and linked by two 
single-strand loop regions. It is the overall shape and stability of the pseudoknot 
that are essential, and not the nucleotide sequence per se. In addition, the space 
between these elements is critical. It is thought that the pseudoknot impedes the 
translation of ribosome. The delay by the ribosome in melting out the secondary 
structural element allows the simultaneous slippage of the P and A site transfer 
RNAs (tRNAs) by one base in the -1 direction. Normal translation then resumes. 
Why coronaviruses employ such a ribosomal frameshifting strategy, however, is 
not well known. It is speculated that the frame shifting mechanism provides a fixed 
ratio of translation products for assembly into a macromolecular complex.  
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1.2.4.3.2 Internal initiation of translation 
The E protein of both IBV and MHV is translated by a cap-independent, 
internal ribosomal entry mechanism (Liu and Inglis, 1992b; Thiel and Siddell, 
1994). Furthermore, if the 3a and 3b ORFs were eliminated from the IBV mRNA, 
translation of the E protein did not occur, implying that the 3a/3b region contains an 
internal ribosome entry site (IRES) for the E protein ORF (Liu and Inglis, 1992b). 
Secondary structures in the 3a/3b region of IBV, which resemble the IRES 
elements of picornaviruses, have been suggested by Le and colleagues (Le et al., 
1994). They predicted a 265-nucleotide sequence in the 3a/3b, which would then 
fold into five stem-loops, form a compact structure through the interaction of two 
pseudoknots.  
1.2.4.3.3 Translation of accessory proteins by leaky ribosomal scanning 
The genomic RNA of BCV and MHV both contain an additional Internal 
ORF within the N protein gene. This ORF is in a different frame from the ORF of 
N protein, and encodes a hydrophobic protein (Fischer et al., 1997a; Senanayake et 
al., 1992). This protein is translated in virus-infected cells through a leaky 
ribosomal scanning mechanism from the bicistronic mRNA of N gene (Senanayake 
et al., 1992).  
1.2.4.4 Assembly and release of coronavirus virions 
Coronaviruses typically contain four structural proteins: a type I S 
glycoprotein required for entry, a phosphorylated N protein that interacts with the 
viral genome to form a helical core, a major type III integral M protein and a minor 
type III E protein (Delmas and Laude, 1990; Hogue and Brian, 1986; Holmes et al., 
1981; Liu and Inglis, 1991; Locker et al., 1992a). Some coronaviruses also contain 
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HE, present as smaller projections in their respective envelopes (Dea and Tijssen, 
1988; King and Brian, 1982; Spaan et al., 1988). Unlike many other enveloped 
viruses, coronaviruses acquire their membrane envelope by budding into the lumen 
of Golgi and pre-Golgi compartments. Early in infection, virus budding occurs at 
the smooth membranes of the intermediate compartment, between rough 
endoplasmic reticulum (RER) and Golgi complex (Narayanan et al., 2003; 
Narayanan and Makino, 2001; Tooze et al., 1984). Later in the infection cycle, 
budding virions can also be detected in the RER and nuclear membrane. 
Subsequently, virions travel in vesicles through the secretory pathway and exit the 
cell through the fusion of these vesicles with the plasma membrane.  
Virus assembly begins with the formation of a helical nucleocapsid, which 
associates with smooth membranes belonging to the ER-Golgi intermediate 
compartment (ERGIC). ERGIC constitute the budding compartment for 
coronaviruses (Krijnse-Locker et al., 1994). The coronavirus N protein has been 
shown to bind viral RNAs in sequence-specific and non-sequence-specific manners 
(Cologna et al., 2000; Robbins et al., 1986; Stohlman et al., 1988b). A specific 
RNA element, usually referred to as a packaging signal or an encapsidation signal, 
determines the selective and specific binding of viral N protein to the genomic 
RNA. For MHV, N protein binds tightly with RNA packaging signal sequence 
located at nucleotide position 1,381 - 1,441, from the 3’ end of MHV gene 1 
(Fosmire et al., 1992). A previous study has shown that when RNA transcripts 
consisted of a non-MHV sequence and the packaging signal were expressed in 
MHV-infected cells, they were packaged into MHV particles (Woo et al., 1997). 
The exact details of N protein-RNA binding and RNA packaging are not well 
understood. In fact, studies suggest that MHV genomic RNA packaging may occur 
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without the N protein, where the M protein is responsible for the packaging of viral 
RNA (Narayanan et al., 2003; Narayanan and Makino, 2001). 
Unlike most other enveloped RNA viruses, coronaviruses employ a 
nucleocapsid-independent strategy to drive virion assembly and budding. From 
studies on MHV and TGEV particle formation, co-expression of E and M proteins 
resulted in the release of virus-like particles (VLPs) from cells, which are similar in 
size and morphology to true MHV and TGEV virions (Baudoux et al., 1998; 
Vennema et al., 1996). In addition, expression of E protein leads to the release of 
E-containing membrane vesicles (Maeda et al., 1999). It is generally believed that 
E protein is required for the formation of coronavirus VLP.  However, co 
expression of SARS-CoV M and N proteins were also leads to VLP formation 
(Huang et al., 2004b).  
The exact functions of E protein during virion assembly is not fully illustrated. 
Its low abundance in virions and in VLPs suggests its may induce membrane 
curvature or to pinch off the neck of the viral particles at the later steops of the 
budding process. However, MHV with E gene deleted was still successfully 
recovered, although this mutant virus shows low growth rate and titer. The plaques 
from this mutant MHV are smaller compared to that from wild type virues (Kuo 
and Masters, 2003). Alanine scanning insertion mutagenesis of the hydrophobic 
domain of the MHV E protein showed that the polar hydrophilic residues within 
the transmembrane domain are important for virus production (Ye and Hogue, 
2007). Substitution of the MHV E gene with other E genes from viruses spanning 
all three groups of coronaviruses showed that the E proteins of group 2 and 3 
coronaviruses could almost fully replace the MHV E protein, while the plaque size 
and viral growth curve are not obviously affected (Kuo et al., 2007). However, E 
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protein from TGEV , a group 1 coronavirus, TGEV, could only functionally 
replace the MHV E protein after acquisition of particular mutations in TGEV E 
protein (Kuo et al., 2007). Because E proteins share a low similarity among 
coronaviruses, these replacements indicates that sequence-specific contacts with 
other viral components may not be essential for E protein to carry out its functions. 
SARS-CoV without E gene was rescued in Vero E6 cells, and this mutant virus 
showed attenuated pathogenicity in vitro and in vivo in hamster models (DeDiego 
et al., 2007). 
How the budding-site is selected for coronaviruses is not well understood. It is 
generally thought that E protein may be responsible for driving the budding process 
by selecting the site of budding, envelope formation and virion assembly. In 
previous reports, the coronavirus M protein was shown to be capable of interacting 
with itself, S, E, HE and N proteins (de Haan et al., 1999; Lim and Liu, 2001; 
Narayanan et al., 2000; Nguyen and Hogue, 1997). The interactions of the M 
protein with these structural proteins may be the means for their incorporation into 
assembled virion particles.  
1.2.5 SARS-CoV proteins  
1.2.5.1 The polyprotein 1a and polyprotein 1ab  
The polyprotein 1a and 1ab of SARS-CoV are generated as precursor 
proteins and subsequently were cleaved into 16 small and functional proteins 
(Ziebuhr, 2004).  The functions of these non-structural proteins are summarized in 
Table 1.4.  
Unlike other coronaviruses, which possess two PLpros, 1 and 2, in the 
polyproteins, SARS-CoV has only one single PLpro (non-structural protein Nsp 3).  
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Nsp1 Host mRNA degradation; translation inhibition; cell cycle arrest; IFN 
signalling inhibition 
Nsp2 Unknown 




) in polyprotein processing; 
poly(ADP-ribose) binding; IFN antagonist; nucleic acid binding; 
deubiquitinating activity; double membrane vesicle formation 
(putative) 
Nsp4 Double membrane vesicle formation (putative) 




) in polyprotein processing 
Nsp6 Double membrane vesicle formation (putative) 
Nsp7 Single-stranded RNA binding 
Nsp8 Primase 
Nsp9 Replicase complex component 
Nsp10 Replicase complex component 
Nsp11 Unknown 
Nsp12 RNA-dependent RNA polymerase 
Nsp13 Helicase; nucleoside triphosphatase activity; RNA 5’-triphosphate 
activity 
Nsp14 3’5’ exoribonuclease; RNA cap formation (guanine-N7)-
methyltransferase 
Nsp15 Endonuclease 
Nsp16 RNA cap formation (2’-O-methyltransferase) 
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It cleaves the N proximal region of 1a and 1ab at 3 sites and releases Nsp 1, Nsp 2 
and itself from precursor polyproteins (Fig. 1.3) (Thiel et al., 2003; Harcourt et al., 
2004). PLpro may also have deubiquitin activity (Barretto et al., 2005).  
Another protease also present in the SARS-CoV polyprotein is the 3C-like 
proteinase (Nsp 5) (Fan et al., 2004), which is a well-characterized and highly 
conserved protein in coronaviruses. It is responsible for the cleavage of the 
remaining part of the polyproteins at 11 sites from Nsp 4 to Nsp 16 (Fig 1.3) (Thiel 
et al., 2003). The SARS-CoV RdRp is in Nsp 12 and the helicase, Nsp13 (Marra et 
al., 2003; Rota et al., 2003; Xu et al., 2003). These two proteins are highly 
conserved in coronaviruses and are used as important criteria in the construction of 
the unrooted and rooted phylogenetic tree of SARS-CoV. Together with other 
cleavage products, RdRp and helicase proteins are essential for the replication and 
transcription of SARS-CoV.   
Structural studies have shown that Nsp 8 is able to interact with both Nsp 7 
and Nsp 9 (Zhai et al., 2005). The super-complex formation between Nsp 7 and 
Nsp 8 is able to interact with double strand RNAs (dsRNAs) and serves to enclose 
and stabilize the dsRNAs. Nsp 9 is structurally similar to two subdomains of the 
SARS-CoV 3C-like proteinase and is supposed to have evolved from a protease. 
Nsp 9 alone is able to bind to RNA (Sutton et al., 2004). These proteins, together 
with RdRp and helicase, are thus predicted to be involved in forming the replication 
and transcription machinery of SARS-CoV.   
Nsp 10 interacts with the cellular oxido-reductase systems and causes 
extensive cytopathic effect (Li et al., 2005c). Nsp 14, Nsp 15 and Nsp 16 are 
predicted functionally as the exonuclease, endoRNAse and mRNA cap-1 
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methyltransferase, respectively (Stadler et al., 2003). SARS CoV nsp16 protein is a 
S-adenosylmethionine-dependent (nucleoside-2′-O)-methyltransferase in the 
presence of its activating partner nsp10. The crystal structure of nsp10/nsp16 
complex was solved at 2.0 Å resolution (Decroly et al., 2011). However, their 
functions are not determined in infected cells. The rest of Nsps are with unknown 
function at present.  
1.2.5.2 Characteristics of structural proteins of SARS-CoV  
1.2.5.2.1 Spike protein  
The S protein is one of the most well characterized proteins of SARS-CoV. 
It has a petal shaped structure, and is evenly projected on the lipid bilayer envelope, 
giving SARS-CoV a crown-like appearance. S protein is a class I fusion protein and 
is highly glycosylated with 23-predicted glycosylated sites (Bosch et al., 2003; 
Hofmann and Pohlmann 2004, Xiao et al., 2003).  
S protein is responsible for the binding of SARS-CoV to host cellular 
receptor. One of the well-defined receptors of SARS-CoV is a metallopeptidase 
ACE2 that is a carboxypeptidase functioning as a polypeptidase enzyme from the 
renal angiotensis system (Li et al., 2003; Hofmann and Pohlmann, 2004). ACE2 is 
expressed in a variety of tissues and organs, permitting widespread of SARS-CoV 
in human body (Li et al., 2005b; Hofmann et al., 2004). Another possible receptor 
reported to bind to the SARS-CoV S protein is the dendritic cell-specific ICAM-
grabbing non-integrin (DC-SIGN) protein, which is found on dendritic cells (Yang 
et al., 2004).  
In other coronaviruses, S protein is cleaved into two domains S1 and S2 by 
the host cellular enzyme furin (Lai and Cavanagh, 1997). However, sequence 
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alignment of murine hepatitis virus S protein with that of SARS-CoV showed the 
lack of essential residues for cleavage by furin. It is therefore likely that the SARS-
CoV S protein is not cleaved into two domains by furin (Yao et al., 2004). Based on 
its functional similarity to the S protein of other coronaviruses, SARS-CoV S 
protein is theoretically divided into two functional domains S1 and S2 (Li et al., 
2005b).  
The S1 region is composed of 600 amino acids and ranges from residues 12 
to 612. It is functionally divided into N terminal domain (12-306) and ACE2-
receptor binding domain (306-667) (Wong et al., 2004). Structural studies showed 
that a gentle concave surface of S2 region cradles the N-terminal lobe of ACE2 
(Prabakaran et al., 2004; Kuba et al., 2005). 14 residues of this loop interact with 18 
residues in ACE2. Asparagine at position 479 and threonine at position 487 in S 
protein are two important residues involved in the specific binding to human ACE2 
(Li et al., 2005b). The receptor-binding region of S1 (400-600) overlaps with a 
neutralizing epitope of S protein; and the latter blocks the binding of S protein to its 
receptor (Yi et al., 2005; Chen et al., 2005).  
The S2 region is from amino acid residues 667 to 1190 and functions as a 
fusion domain. It characterizes S proteins as class I fusion protein with a fusion 
peptide, two heptad regions and a transmembrane domain. The transmembrane 
domain anchors S protein on the viral envelope. Upon binding of S protein to 
ACE2, conformational change of the coiled – coil structure brings the virus 
membrane coming into close proximity to host cell membrane and simultaneously 
exposes the fusion peptide for insertion into the host cell membrane, thereby 
triggering the fusion of two membranes (Ingallinella et al., 2004; Tripet et al., 
2005;). The S protein of SARS-CoV mediates membrane fusion by means of pH-
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independence (Yang et al., 2004) or dependence (Simmons et al., 2004), leading to 
the direct release of genomic RNA into the cytoplasm of host cells (Zhang and Yap, 
2004; Smith and Helenius, 2004) or the internalization of SARS-CoV through 
cellular endocytosis (Dimitrov, 2004).  
1.2.5.2.2 Envelope and Membrane proteins  
E and M proteins are two major components of the virus envelope. 
Association of E protein and M protein is essential for the assembly of VLPs. When 
co-expressed in cells, M and E protein of SARS-CoV were able to form 
sedimentable particles. Location of these two proteins in the ER, Golgi and 
intermediate compartments are essential for the assembly and release of virus 
particles through the secretory pathways of cells. The requisite ratio of E to M for 
VLP formation is 1:5 (Huang et al., 2004a; Ho et al., 2004).  
M protein is a glycosylated protein comprising of 221 amino acids; it forms 
three transmembrane helices domain from residues 15 to 99, and a 121 amino acid 
hydrophilic domain on the inside of virus particles (Marra et al., 2003).  
E protein is indispensable in the assembly of VLPs. It is a small protein with 
76 amino acids. SARS-CoV E protein is less similar to other coronavirus envelope 
proteins (Arbely et al., 2004).  
1.2.5.2.3. Nucleocapsid protein  
SARS-CoV N protein consists of 422 amino acids and is minimally 
homologous to other coronavirus proteins. It is essential for the packaging of the 
RNA genome. Two independent RNA binding domains of N protein are located at 
the N- and C-terminal regions of the protein, respectively. Deletion of these two 
domains greatly diminishes the RNA binding capability of N protein. During 
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packaging, N protein binds to a specific RNA sequence of the genomic RNA 
located the 3' terminal region of ORF1b (Huang et al., 2004b).  
N protein of SARS-CoV is localized mainly to the cytoplasm, although it 
can also be found in the nucleus (You et al., 2005; Rowland et al., 2005). N protein 
is capable of forming dimers and high order multimers. A small ubiquitin-like 
modifier (SUMO) is reported to attach covalently to N protein at lysine residue 62 
(Li et al., 2005b). The binding of SUMO to N protein promotes homo-
oligomerization of the latter. Caspase 3 has also been shown to cleave N protein; 
cleavage induces T-cell response and activates the activator protein 1 signal 
transduction pathway as well. N is also implicated in the induction of host immune 
response through the activation of nuclear factor kappa B (NFκB) protein (Tan et 
al., 2005; Liao et al., 2005).  
1.2.5.3 Characteristics of SARS-CoV putative proteins  
SARS-CoV encodes a unique set of ORFs, which do not share homology 
with any of the known coronaviruses. They are ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b and 
9b, which are predicted to encode the accessory proteins of SARS-CoV. Among 
these SARS-CoV accessory proteins, protein 3a, 7a, 8a and 9b have been detected 
in patients’ sera (Guo et al., 2004; Qiu et al., 2005b; Tan et al., 2004a).  
In other coronaviruses, certain subgroup-specific accessory proteins are 
dispensable for viral replication, or at least in the cell culture system. They may, 
however, play important roles in the interactions between host and virus, and 
contribute to viral fitness (Brown et al., 1995; Lai and Cavanagh, 1997).  
A number of SARS-CoV accessory proteins have been characterized. One 
of the well-characterized accessory proteins of SARS-CoV is protein 3a. It is 
encoded by ORF3a on subgenomic mRNA 3, and is the largest accessory protein of 
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SARS-CoV. Expression of protein 3a is detected in patients’ lung specimen as well 
(Yu et al., 2004; Zeng et al., 2004; Tan et al., 2005b). Protein 3a is located in the 
perinuclear region and Golgi apparatus, and interacts with structural proteins S, M 
and E (Qiu et al., 2005; Yuan et al., 2005a). In addition, it is transported to the 
surface of host cells and undergoes endocytosis (Tan et al., 2004d). Protein 3a is 
also found to stimulate the expression of fibrinogen (Tan et al., 2005e), induce 
apoptosis in Vero E6 cells (Law et al., 2005), and is proposed as a novel structural 
protein (Shen et al., 2005). 
ORF3b encodes protein 3b of SARS-CoV. It is a 154 amino acid protein 
and is localized to the nucleus (Yuan et al., 2005c). It induces cell cycle arrest at 
G0/G1 phase (Yuan et al., 2005b). It is predicted that the protein is translated by an 
internal ribosomal entry mechanism (Snijder et al., 2004).  
Protein 7a is encoded by ORF7a of the subgenomic mRNA 7 and is 
composed of 122 amino acids. It is likely a type I membrane protein (Nelson et al., 
2005; Bartlam et al., 2005). Its C-terminal tail contains a typical ER retrieval motif. 
Protein 7a is located in the perinuclear region in SARS-CoV infected cells 
(Fielding et al., 2004). Transient expression of the protein induces apoptosis in 
different cell lines via a caspase dependent pathway (Tan et al., 2004c).  
Protein 6 is a 7.5 kDa protein, which is located in the endoplasmic 
reticulum and stimulates cellular DNA synthesis when expressed in mammalian 
cells (Geng, 2005), has also be shown to incorporate into the virion-like-particles 
(Huang, 2007). It accelerates murine coronavirus infections and enhances the 
virulence of MHV (Pewe, 2005; Tangudu, 2007). However, SARS-CoV with 
deleted ORF6 (rSARS-CoVΔ6) can still infect mice, although the replication 
efficiency of rSARS-CoVΔ6 is not as high as SARS-CoV (Zhao et al., 2009).  
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ORF6 was reported to interfere with both the interferon pathway and the apoptosis 
pathway (Kopecky-Bromberg et al., 2007; Ye et al., 2008). The detailed 
mechanism by which protein 6 enhances virulence is still unknown.  
Characteristics of the rest of the accessory proteins of SARS-CoV have not 
been elucidated yet. Protein 7b is predicted to be a 44-amino acid protein. It is 
encoded by ORF7b of the subgenomic mRNA 7 (Marra et al., 2003). Transient 
expression of protein 7a induces apoptosis in different cell lines via a caspase-
dependent pathway (Tan et al., 2004c).  
Protein 8a of the human severe acute respiratory syndrome coronavirus 
not only promotes viral replication, it also induces apoptosis (Chen, 2007). Protein 
8b down-regulates the expression of the envelope protein in infected cells (Keng, 
2006). 
Protein 9b is composed of 98 amino acids. The crystal structure of 9b has 
been solved in the year 2006. The protein has a dimeric tent-like beta structure 
with an amphipathic surface, and a central hydrophobic cavity that binds lipid 
molecules. This cavity is likely to be involved in membrane attachment; in 
mammalian cells, ORF-9b associates with intracellular vesicles, consistent with a 
role in the assembly of virions (Meier, 2006). Analysis of intraviral protein-
protein interactions of the SARS coronavirus ORFeome showed that 9b interacts 
with most of the non-structure proteins and structure proteins (Brunna, 2007). 
These results also imply that 9b may function during virion assembly. However, 
more evidence is required to support this hypothesis.  
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1.3. CORONAVIRUS GENETICS AND REVERSE GENETICS 
The reverse genetics system allows for the production of defined, genetically 
modified viruses, which are important for the analysis of the molecular biology and 
pathogenesis of coronaviruses. However, systematic assembly of a full-length 
coronavirus infectious clone has been hampered by the large size of the genome, 
regions of chromosomal instability and the inability to synthesize full-length 
transcripts (Masters, 1999). Coronaviruses have the largest RNA genome of all 
known RNA viruses, and a number of cDNAs in the region of the replicase gene 
are unstable in bacteria. All these hampered the generation of a full-length 
infectious cDNA clone. Nonetheless, several different methods have been 
described for the assembly of coronavirus full-length cDNAs throughout the years.  
The first method involves the assembly of a TGEV full-length cDNA in a low 
copy-number bacterial artificial chromosome (BAC), downstream of a viral RNA 
polymerase II promoter. Transfection of this construct into susceptible cells 
resulted in the recovery of recombinant virus (Almazan et al., 2000). Further 
stabilization of the full-length BAC clone in bacteria was achieved through the 
insertion of a eukaryotic intron into either of two positions in the toxic region of 
TGEV cDNA (Gonzalez et al., 2002). This allowed the stable propagation of BAC 
for over 200 generations.  
The second system involves the in vitro assembly of TGEV full-length cDNA 
through the usage of a serious of contiguous cDNAs with engineered unique 
restriction sites. T7 RNA polymerase derived RNA transcripts of full-length cDNA 
were used to generate recombinant viruses (Yount et al., 2000); the boundaries of 
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the subcloned genomic cDNA could be easily manipulated for site-directed 
mutagenesis. Importantly, some fragment boundaries were arranged in such a way 
that the unstable cDNA regions were interrupted. This approach was facilitated by 
restriction enzymes that cut at a distance from their recognition sequences, thereby 
ensuring that no additional, rearranged sequences were generated during the 
ligation. This in vitro assembly technique has since been successfully used to 
engineer the genomes of MHV, SARS-CoV and IBV (Fang et al., 2006; Youn et 
al., 2005; Yount et al., 2002; Yount et al., 2003). 
The third system involves the in vitro assembly of the HCoV full-length 
cDNA, followed by cloning into the genome of vaccinia virus (Thiel et al., 2001). 
Infectious HCoV RNA synthesized in vitro from vaccinia virus DNA was 
transfected into the cells and resulted in the recovery of recombinant virus. The use 
of vaccinia as a vector has allowed manipulation of the resulting cloned cDNA by 
methods that have previously been developed for poxvirus reverse genetics. 
Originally applied to HCoV-229E, it has since been used to engineer the genome of 
IBV and MHV (Casais et al., 2001; Coley et al., 2005).  
The availability of the reverse genetics system has been important in the 
genetic analysis of a number of coronavirus genes. Mutant viruses generated by 
full-length infectious IBV cDNA have also provided evidence that neither gene 3 
nor gene 5 of IBV is essential for replication (Casais et al., 2005; Hodgson et al., 
2006). In addition, through the manipulation of a full-length infectious construct of 
TGEV, it was demonstrated that subgenomic transcription is heavily influenced by 
upstream flanking sequences (Curtis et al., 2004). Coronavirus reverse genetic 
investigations have also led to the development for vaccines, expression systems 
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and gene delivery vectors (Alonso et al., 2002; de Haan et al., 2003b; de Haan et 
al., 2005; Haijema et al., 2004; Thiel et al., 2003).  
1.4 THESIS OBJECTIVES 
SARS-CoV accessory protein ORF9b and ORF6 were studied in this PhD 
project. 
In the first part of this dissertation, the following aspects of SARS-CoV 
ORF9b were examined. The expression of SARS-CoV ORF9b was confirmed both 
in vivo and in mammalian cells. The translation mechanism of SARS-CoV ORF9b 
was illustrated via the introduction of mutations at the flanking area of translation 
initiation sites. Functions of SARS-CoV ORF9b in virus assembly and release were 
also studied using the virion like particle (VLP) system. Mechanisms employed by 
SARS-CoV 9b to carry out its functions were illustrated using techniques including 
immunoprecipitation, immunoblotting and immunofluorescence as well. 
In the second part of this dissertation, the effects of SARS-CoV ORF6 on 
human cell transcription profile were studied with microarray analysis. Functions of 
ORF6 in interferon production were then examined when the pathway was 
activated with polyinosinic:polycytidylic acid [poly(I:C)] treatment. Interactions 
between ORF6 and key transcription factors in the interferon pathway were 
illustrated using techniques including immuno-precipitation, immuno-blotting and 
immuno-fluorescence. The function of ORF6 in cell death was examined examined 
as well.  
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CHAPTER 2.  MATERIALS AND METHODS 
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2.1 LIST OF CHEMICALS, ANTIBODIES AND REAGENTS 
Trypsin solution Invitrogen (USA) 
Penicillin-Streptomycin stock solution Invitrogen (USA) 
Fetal bovine serum (FBS) Hyclone (USA) 
bovine serum albumin (BSA) Sigma-Aldrich 
(USA) 
Luria-Bertani (LB) medium Sigma-Aldrich 
(USA) 
Antibiotics ampicillin and kanamycin Sigma-Aldrich 
(USA) 
5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside  
(X-Gal) Bio-rad (USA) 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Bio-rad (USA) 
Dithiothreitol (DTT) and lysozyme Sigma-Aldrich 
(USA) 
Restriction enzymes New England 
Biolabs (USA) 
1 kb DNA ladder and 100 bp DNA ladder New England 
Biolabs (USA) 
Pfu DNA polymerase and Taq DNA polymerase Fermentas 
Tri-reagent Molecular Research 
Center 
Goat-anti-mouse, goat-anti-rabbit, rabbit-anti-goat antibody DakoCytomation 
(Denmark) 
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6×His monoclonal antibody/HRP conjugates BD Biosciences 
(USA) 
anti-EGFP monoclonal antibody BD Biosciences 
(USA) 
anti-HA tag polyclonal antibody BD Biosciences 
(USA) 
anti-luciferase monoclonal antibody Sigma-Aldrich 
(USA) 
anti-Sanpin polyclonal antibody abCam 
anti-PARP 1 polyclonal antibody Cell Signaling 
anti-BIRC5 antibody Cell Signaling 
anti-STAT1 antibody  Cell Signaling 
anti-FLAG M2 agarose affinity gel Sigma-Aldrich 
(USA) 










Enhanced chemiluminescence (ECL) reagents Amersham 
Biosciences (USA) 
Antibodies against SARS-CoV proteins and IBV proteins are raised in LDX lab. 
The phosphate-buffered saline (PBS) used in all experiments is composed of 137 
mM NaCl, 2.7 mM KCl, 4.3 mM KH2PO4 and 1.4 mM K2HPO4·7H2O, pH 7.3. 
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2.2 CELL CULTURE 
2.2.1 Cell lines 
H1299 cells (Human lung cancer cells), HeLa cells (human cervical 
adenocarcinoma cells) and Vero cells (African green monkey cells) were used for 
all the expression assays. 
2.2.2 Cell culture 
H1299, HeLa and Vero cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma) with 4500 mg/L glucose, supplemented with 10% fetal 
bovine serum (FBS) (Hyclone), 100 units/ml penicillin and 100 units/ml 
streptomycin (Invitrogen). The cells are incubated at 37°C and 90% humidity level 
with 5% CO2. 
For subculturing, cells were washed with ice-cold PBS once. Subsequently, 
a buffered salt solution (Invitrogen) containing 0.5% (w/v) trypsin and 0.2% (w/v) 
EDTA was used to dissociate adherent cells from tissue culture flasks. Cells were 
further detached by DMEM medium and collected by centrifugation at 500×g for 5 
min. After re-suspension in fresh DMEM medium with 10% FBS and 1% PS, cells 
were seeded in new culture flasks. 
2.2.3 Cell stock preparation 
To prepare cell stocks, cells were trypsinized and collected by 
centrifugation at 500 × g for 5 min. After re-suspension in cell stock medium 
(DMEM medium with 10% FBS, 1% PS, and 20% glycerol), cells were transfer to 
2 ml cryo-tube (NUNC) by aliquots and stored in liquid nitrogen. 
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2.2.4 Viruses 
All genomic information of SARS-CoV is based on SARS-CoV Sin2774 
(GenBank accession no. AY283798). All genomic information of IBV is based on 
Beaudette strain of IBV( GenBank accession no. DQ001339). 
Vero cell-adapted Beaudette strain of IBV stock (Liu and Inglis, 1992; 
Shen, Law, and Liu, 2004; Shen, Wen, and Liu, 2003) was prepared by infection of 
Vero cells with 0.1 plaque forming unit (pfu) of IBV per cell, followed by 
incubation at 37°C in a humidified 5% CO2 atmosphere. Virus stocks were made 
through three repeated freeze-thaw cycles and kept at -80°C in 0.5-1ml aliquots 
until use. Mock virus stocks were similarly made using three repeated freeze-thaw 
cycles of Vero cells.  
A recombinant IBV containing luciferase reporter gene (IBV-Luc) was 
constructed by replacing 3a3b ORF with the firefly luciferase gene, and another 
recombinant IBV (rIBV) generated from an infectious clone was used as the wild-
type control (Shen et al., 2009).  
A recombinant IBV containing luciferase reporter gene (IBV-Luc) was 
constructed by replacing 3a3b ORF with SARS ORF6. 
All recombinant and wildtype IBVs were propagated in Vero cells in FBS-
free DMEM.  
2.2.5 Virus infection 
Confluent monolayers were first subcultured and seeded in appropriate 
culture vessels overnight. Cells were then washed once with PBS and changed to 
FBS free medium prior to virus infection, and inoculated with either recombinant 
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or wildtype IBV at appropriate multiplicities of infection (MOI) depending on the 
experiment performed. 
2.2.6 Virus titration 
Confluent monolayers of Vero cells on six-well plates were infected with 
100µl of 10-fold serially diluted virus stock. After 1 h of incubation at 37 ºC, cells 
were washed twice with PBS and cultured in 3 ml of DMEM containing 0.5% 
carboxymethyl cellulose for 3 days. The cells were fixed and stained with 0.1% 
toluidine blue. The number of plaques was counted and the virus titre was 
calculated as pfu/ml (pfu: plaque forming unit).  
2.3 MOLECULAR CLONING 
2.3.1 Preparation of E. coli competent cells 
Escherichia coli strain DH5α or BL21DE3 was streaked onto a LB plate 
(1% bacto-tryptone, 0.5% bacto-yeast extract, 1% NaCl and 1.5% agar, pH 7.0) 
and incubated at 37°C overnight. Single colony was picked and grown in 2 ml LB 
broth at 37°C overnight with shaking at 220 rpm. An inoculum of the culture was 
diluted 1:100 into 400 ml LB medium and incubated at 37°C with vigorous shaking 
until the absorbance at 660 nm (A660) reached 0.6-0.8. The culture was chilled on 
ice for 30 min and bacterial cells were collected with centrifugation at 4,000 g for 
15 min at 4°C. The pellet was re-suspended in 40 ml pre-cooled 0.1M CaCl2 
solution and incubated on ice for 1 hr. After centrifugation at 4,000 g for 15 min at 
4°C, the pellet was re-suspended in 4 ml solution of 0.1M CaCl2 with 20% 
glycerol. The competent cells were stored in aliquots at -80°C. 
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2.3.2 Transformation of competent cells 
An aliquot of E. coli competent cells were pre-thawed on ice before 
transformation. DNA plasmid (10ng) or ligation products were added to competent 
cells and incubated on ice for 15-20min. The mixture was heat shocked at 42°C for 
1 min and immediately chilled on ice for 2 min. One ml 2 × LB broth was then 
added into the mixture and incubated at 37°C with vigorous shaking for 45-60 min. 
The suspension was subsequently spread onto LB plates containing 100µg/µl 
ampicillin or 50µg/µl kanamycin. The LB plates were incubated at 37°C overnight 
and single colonies were picked for mini-scale DNA preparation and further 
characterization. 
2.3.3 Restriction enzyme digestion of DNA 
The restriction endonuclease digestion mixture was prepared as follows: 1-
3µg of DNA, appropriate 1 × restriction digestion buffer and 10 units of each 
restriction enzyme. The mixture was topped up with distilled H2O to a total volume 
of 20-50µl and incubated at 37°C for 2 h. Experimental details are subjected to 
change according to the manufacturer’s instruction for different restriction 
enzymes. 
To prevent singly-digested vector from self-ligation, calf intestinal alkaline 
phosphatase (CIP) (New England Biolabs) was used to remove the phosphate 
group from the 5’-end of the DNA strand. Typically, 1 unit of CIP was added 
directly to the restriction reaction mixture in the end of the 2 h digestion and 
incubated for another 30 min at 37°C. 
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2.3.4 End-filling of DNA fragment 
End-filling of digested DNA fragment with 5’ or 3’ overhangs were carried 
out in a total volume of 50 µl reaction containing 2 µg of linearized DNA 
fragments, 1 × buffer, 33 µM of each dNTP and 5 units of Klenow Fragment and 
incubate at 25°C for 15 min. 
2.3.5 Polymerase chain reaction (PCR) 
Primers used in PCR were ordered from Proligo (Sigma). Briefly, PCR 
reaction mixture included 10-20 ng of DNA template, 50 pM of the forward and 
the reverse primers, 2.5 units of DNA polymerase, 1×PCR buffer supplemented 
with 1.75 mM MgCl2, together with 250 µM each of deoxy-adenine (dATP), 
deoxy-cytosine (dCTP), deoxy-guanine (dGTP) and deoxy-thymidine (dTTP) 
nucleotides (Promega). The reaction was carried out by 1 cycle of denaturation at 
94°C for 2 min, followed by 30-35 cycles of denaturation at 94°C for 30 sec, 
primer annealing for 30-60 sec and DNA extension at 72°C. The final cycle of 
DNA extension was carried out at 72°C for 7 min. The reagent mixture and thermal 
cycle set-up were slightly adjusted to optimize the product yield and specificity. 
2.3.6 Site-directed mutagenesis PCR 
Site-directed mutagenesis PCR was achieved using the QuikChange site-
directed mutagenesis kit (Strategene). Typically, PCR reaction containing 2.5 units 
of Pfu Turbo
TM
 DNA polymerase and 1×buffer, 30 ng of plasmid DNA template, 
125 ng of each mutagenic primers and 250 µM of each deoxynucleotides (dNTPs) 
was carried out by 1 cycle of denaturation at 95°C for 30 sec followed by 18 cylces 
of denaturation at 95°C for 30 sec, annealing at 55°C for 1 min and extension at 
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68°C for 5-7 min. The PCR reaction was then digested by 20 units of DpnI (New 
England Biolabs) at 37°C for 1 hr and was ready for transformation into E. coli 
cells. 
2.3.7 Gel purification of DNA 
Gel purification of DNA was performed using the Qiaquick
TM
 Gel 
Extraction Kit from QIAGEN. Restriction reaction products were separated in 1% 
agarose gel. Visualized under long-wavelength UV-transilluminator, the DNA 
bands of interest were excised with scalpels and the gel slices were dissolved in 
appropriate volume of dissolving buffer QG according to the manufacturer’s 
instruction. Complete melting of gel slice was achieved by incubation at 55°C for 
10 min with occasional vortex. The dissolved mixture was applied onto the 
Qiaquick
TM
 column for DNA purification. After washing, the DNA fragments of 
interest were eluted with nuclease free water to a desired volume. 
2.3.8 PCR purification 
PCR products were purified by Qiaquick PCR purification Kit (Qiagen). 
Briefly, 250µl of PB buffer were added to a 50µl PCR reaction. The mixture was 
applied onto Qiaquick column. After washing, the DNA fragments of interest were 
eluted with nuclease free water to a desired volume. 
2.3.9 Agarose gel electrophoresis 
DNA samples were separated by electrophoresis in the 1.0-2.0% (w/v) 
agarose gels prepared with TAE buffer (40 mM Tris-acetate and 2 mM EDTA), 
supplemented with 1 µg/ml ethidium bromide. 6 × DNA loading buffer [0.25% 
(w/v) of bromophenol blue and 0.25% (w/v) xylene cyanol FF and 40% (w/v) 
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sucrose in H2O] was added to each DNA sample before loading to the agarose gel. 
DNA bands were visualized under UV illumination. 
2.3.10 DNA Ligation 
The purified vector and insert DNA fragment were mixed at a molar ratio of 
1:3, together with 1 unit of T4 DNA ligase (New England Biolabs) and 1 × T4 
ligation buffer in a total volume of 10 µl. Ligation mixture was incubated at 16°C 
waterbath overnight. 
2.3.11 DNA preparation 
The QIAprep
®
 Spin Miniprep Kit was used for small-scale DNA 
preparation from E. coli cells. Single colony was inoculated into 5 ml LB medium 
with proper antibiotics at 37°C with shaking overnight. Cells were pelleted by 
centrifugation at 14,000 rpm for 1 min and re-suspended in P1 solution containing 
100 mg/ml RNase A. Cells were subsequently lysed in P2 solution and neutralized 
by P3 solution prior to centrifugation at 14,000 rpm for 10 min. The supernatant 
was applied onto the QIAprep
®
 spin column. After washing, the DNA was eluted 
with 50µl nuclease free water. 
The QIAGEN
®
 Plasmid Midi Kit was used for large-scale DNA 
preparation. Single colony was inoculated into 5 ml LB medium with proper 
antibiotics at 37°C with shaking for 8 h and the culture was inoculated into large 
volume of LB medium with antibiotics with a 100 times dilution shaking at 37°C 
overnight. Cells were pelleted by centrifugation at 4,000 g for 15 min at 4°C and 
re-suspended in P1 solution containing 100 mg/ml RNase A. Cells were 
subsequently lysed in P2 solution and neutralized by P3 solution prior to loading 
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onto to the QIAfilter
TM
 Midi Cartridge. The filtrate was subsequently applied onto 
the QIAGEN-tips. After washing with QC buffer, the DNA was eluted with 5 ml 
QF solution. DNA was then precipitated with isopropanol and re-suspended in 100-
200 µl of nuclease-free water. 
2.3.12 Automated DNA sequencing 
Plasmid DNA (300 ng) was added to a mixture of total volume of 10 µl 
containing 3.2 pmol of primer, 1 × Big Dye termination (ver 3.1). Sequencing PCR 
reaction was carried out by 25 cycles of denaturation at 96°C for 10 sec, annealing 
at 50°C for 5 sec and extension at 65°C for 4 min. The reaction mixture was 
purified by adding 2 volumes of 100% ethanol, 0.1 volume of 3M sodium acetate 
(pH 5.2), and incubated on ice for 10 min before centrifugation at 14,000 rpm for 
20 min. The pellet was washed twice with 70% ethanol and air-dried. Sequence 
was determined on an Applied Biosystems Model 3730XL automatic DNA 
sequencer and analyzed by Chromas program. 
2.4 IN VITRO TRANSCRIPTION 
5µg plasmid DNAs were linearized and purified by phenol/chloroform and 
ethanol precipitated before transcription. The reaction was performed using 
mMESSAGE mMACHINE
®
 RNA transcription kit (Ambion). The mixture 
contains 1µg linearized DNA, 1×transcription buffer, 2.5 mM ribonucleotides 
(NTPs), 2µl Enzyme Mix in a total volume of 20µl. Transcription was done by 
incubating the mixture at 37°C for 1 hr prior to DNase I digestion at 37°C for 
another 15 min.  
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2.5 RNA MANIPULATION 
2.5.1 Isolation of total RNA from mammalian cells 
Monolayer cells were washed twice with ice-cold PBS prior to the addition 
of Tri-Reagent. After incubation at room temperature for 10 min with shaking, 
cells were scraped and transferred to microcentrifuge tubes. Chloroform (0.2 
volume of Tri-Reagent) was added to the lysates and vortexed vigorously before 
centrifugation at 14,000 rpm for 20 min at 4°C. The aqueous phase was transferred 
to a new tube and was mixed with equal volume of chloroform. After 
centrifugation at 14,000 rpm for 10 min at room temperature, the aqueous phase 
was transferred to a new tube and RNA was precipitated with 100% ethanol at -
20°C for at least 30 min. The mixture was centrifuged at 14,000 rpm for 20 min at 
4°C and the pellet was washed with RNase free 70% ehthanol. RNA was re-
suspended with proper volume of RNase-free water. To avoid DNA contamination 
in subsequent analysis, DNase treatment was carried out and further purified using 
RNeasy
®
 Mini Kit (Qiagen) according to manufacturer’s instructions. 
2.5.2 Reverse transcription 
RNA was reverse transcribed using a first-strand cDNA synthesis kit 
(Expand
TM
, Roche). One µg of total RNA was mixed with 20pmol primer and 
denatured at 65ºC for 10 min. The mixture was immediately chilled on ice before 
the addition of 4 µl of 5 × Expand reverse transcriptase buffer, 2µl of 100 mM 
DTT, 20 units of RNase inhibitor, 2µl of 10 mM dNTPs and 50 units of Expand 
reverse transcriptase. The mixture was incubated at 43ºC for 1 h. An aliquot of the 
reaction was used for PCR. 
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2.5.3 RNA interference (RNAi)  
Small interfering RNAs (siRNA) were purchased from Dharmafect 
(Dharmacon). Transfection of siRNA into H1299 cells grown to 60% confluence 
was performed using DharmaFECT transfection reagent (Dharmacon) according to 
the manufacturer’s instructions. Briefly, a 2 µM siRNA solution in serum-free 
medium was mixed with the appropriate cell-line-specific DharmaFECT 
transfection reagent, also in serum-free medium of equal volume, mixed briefly and 
incubated at room temperature for 20 min. The total volume of the transfection mix 
is dependent on the size of the plate format used. Culture medium was then 
removed from the cells, and the transfection mix added to them. Transfected cells 
are incubated at 37°C with 5% CO2 for 48 h (for mRNA analysis) or 72 h (for 
protein analysis). 
2.6 PROTEIN EXPRESSION AND ANALYSIS 
2.6.1 Transient expression of plasmid DNA in mammalian cells 
H1299 cells of 80-90% confluence in 6-well plates were transfected using a 
recombinant vaccinia virus system. Cells were infected with recombinant 
vaccinia/T7 virus of MOI 1 for 1 h. The supernatant was removed and cells were 
washed once with PBS before transfection with 0.4µl plasmid DNA, using 
Effectene Transfection Reagent (Qiagen) according to the manufacturer’s 
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2.6.2 Coupled in vitro transcription and translation 
Plasmid DNA was translated in rabbit reticulocyte lysates (RRL) using a 
transcription coupled-translation (TnT) system (Promega). Briefly, 1µl circularized 
plasmid DNA was incubated with 25µl RRL together with RNase inhibitor, minus-
methionine amino acids mix in the presence of 50µCi of [
35
S]-methionine 
(Amersham Biosciences) at 30°C for 60-90 min. The mixture was stored at -80°C. 
2.6.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were prepared by adding 2×Laemmli’s sample buffer [100 mM 
Tris-HCl pH 6.8, 4% SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol and 
10% (v/v) ß-mercaptoethanol] and were heated at 95°C for 5 min before loading 
onto SDS-PAGE. The resolving gels of various concentrations (10%, 12% or 15%) 
and 5% stacking gels were cast between two glass plates. The gels were run in the 
Bio-Rad Mini-PROTEAN II system in a reservoir of running buffer [25 mM Tris-
HCl pH 8.3, 192 mM glycine and 0.1% SDS] at 20 mA per gel. 
After electrophoresis, gels containing [
35
S]-methionine were fixed in 50% 
methanol and 10% acetic acid for 45 min before the signal was enhanced with 
Amplify
TM
 (Amersham Biosciences) for 15 min. Gels were dried under vacuum at 
80ºC for 1 h and exposed to X-ray film (Amersham Biosciences) for 
autoradiography at -80ºC overnight. 
Gels for western blotting were electroblotted to polyvinylidene difluoride 
(PVDF) membrane (Bio-Rad) at 4ºC using the Bio-Rad Trans-Blot
TM
 system. The 
transfer buffer contains 24 mM Tris-base, 192 mM glycine and 20% methanol. 
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2.6.4 Western Blotting 
After the membrane was blocked in blocking buffer [PBS with 10% 
skimmed milk powder and 0.1% Tween 20] at room temperature for 1 h, it was 
incubated for 1 h at room temperature in a dilution of a specific antiserum in 
blocking buffer. After washing thrice for 10 min each with PBST [PBS with 0.1% 
Tween 20], the membrane was incubated with proper IgG conjugated with 
horseradish peroxidase (HRP) diluted in blocking buffer for 45 min at room 
temperature. After three washes with PBST, the membrane was subjected to 
chemiluminescence detection with the ECL kit (Amersham Biosciences). To re-
probe the same membrane with another antibody, the membrane was incubated in 
stripping buffer [62.5 mM Tris-HCl pH 6.7, 100 mM ß-mercaptoethanol and 2% 
SDS] at 55ºC for 30-45 min, followed by blocking again. 
2.6.5 Immunoprecipitation 
Transfected mammalian cells were washed once with ice-cold PBS, and 
lysed with lysis buffer [140 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.5% (v/v) NP-
40]. Cell debris was removed by centrifugation at 14,000 rpm for 20 min at 4ºC. 
The supernatant was incubated with 1µg of appropriate antiserum for 2 h at room 
temperature with shaking before incubation with 50µl protein A-agarose beads for 
2 h at room temperature. After washing with lysis buffer three times, the beads 
were incubated with 2 × Laemmli’s sample buffer and boiled for 5 min. 
2.6.6 Indirect immunofluorescence 
Cells were fixed with 4% paraformaldehyde for 10 min at 16 h post-
transfection, washed three times with 1 x PBS, permeabilized with 0.2% Triton
 
X-
100 for 10 min at RT, and washed three
 
times with 1 x PBS. Specific antibodies 
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were used to detect target proteins. Cells were then subjected to three washes with 
PBS and incubated with IgG conjugated to FITC (DAKO) diluted in PBS (1:30~ 
1:50) for 2 h at 4
o
C. After three times washes with PBS, cells were mounted with 
glass coverslips using a mounting medium (DAKO). Images were collected with a 
META 510 confocal laser-scanning microscope (Zeiss).  
2.6.7 Luciferase assay 
Cells were seeded in 6-well dishes and incubated in at 37ºC, 5% CO2 for 
16-18 h. 4µg of each plasmid DNA containing luciferase genes were introduced 
into cells in serum-free DMEM by Lipofectamine 2000 reagent (Invitrogen) 
according to manufacturer’s instruction. After 4 h post-transfection, the medium 
was replaced with fresh DMEM supplemented with 10% FBS, 1% ampicillin and 
1% streptomycin, and continue incubation for 16-18 h. Cells were washed three 
times with PBS, lysed with 100-300µl of passive lysis buffer (Promega). A 
luciferase reporter assay was performed according to the manufacturer’s 
instructions using the TD-20/20 luminometer (Turner Biosystems). Each 
transfection and luciferase assay was repeated at least three times. 
2.7 Lipid rafts isolation 
Cell monolayers were washed once in ice-cold PBS, resuspended in
 
MBS 
buffer (25 mM 4-morpholineethanesulfonic acid and 150 mM
 
sodium chloride [pH 
6.5] containing a protein inhibitor cocktail
 
[Roche] at 1 tablet/50 ml or 1 mM 
PMSF), lysed by Dounce homogenization
 
and sonication (three 30-s bursts; 
Polytron), and treated with
 
1% Triton X-100 (MBST buffer) on ice for
 
30 min. 
Following detergent treatment, permeabilized cell lysates
 
were mixed 1:1 with a 
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90% sucrose solution and overlaid with
 
discontinuous layers of 35% and 5% 
sucrose. Gradients were resolved
 
by centrifugation in a Beckman SW41 rotor at 
160,030 x g (36,000
 
rpm) for 18 h at 4°C.
 
Fractions were sequentially collected 
starting from
 
the top to the bottom of the tube after centrifugation. Proteins in each 
fraction were resolved by SDS-PAGE and detected by Western analysis with the 
appropriate primary and secondary antibodies.  
2.8 FLUORESCENCE-ACTIVATED CELL (FACS) ANALYSIS 
Cells were harvested, pelleted and washed with pre-chilled PBS before fixing 
with 70% ethanol and incubation at 4°C for at least 90 min. The cells were 
subsequently pelleted and washed with PBS twice prior to the addition of 10ug 
RNase A to each tube. The cells were then incubated at room temperature for 5 min 
prior to the addition of 10ug of propidium iodide to each tube, and another round of 
incubation for 20-30 min in the dark. FACS analysis was performed on a BD™ 
LSR II Flow Cytometer System (BD Biosciences). 
2.9 GENERATION OF RECOMBINANT IBV AND VIRUS ASSAY 
METHODS  
2.9.1. In vitro assembly of full-length cDNA clones 
construct a full-length IBV clone, five plasmids which contain five fragments 
(A to E) spanning the entire IBV genome were constructed in our lab (Fang et al., 
2006). Briefly, five fragments spanning the entire IBV genome were obtained by 
RT-PCR from Vero cells infected with Vero cell-adapted IBV P65. To facilitate 
the assembly of the full-length cDNA in vitro, restriction sites for either BsmBI or 
BsaI were introduced into both the 5’ and 3’ ends of the fragments (Fig. 2.1). The 
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PCR products were purified from agarose gels and cloned into pCR-XL-TOPO 
(Invitrogen) or pGEM-T Easy (Promega) vectors. Subsequently, fragment A was 
removed from pCR-XL-TOPO by digestion with NheI and EcoRI, and subcloned 
into pKT0 vector. In fragment A, 19-nucleotide long T7 promoter sequence was 
inserted into the 5’ end of the IBV genome to facilitate in vitro transcription by T7 
polymerase (Fig. 2-1). The plasmids were digested with BsmBI (fragment A) or 
BsaI (fragments B, C, D and E). The digested products were separated with 
electrophoresis using 0.8% agarose gels containing crystal violet. Specific bands at 
given size corresponding to each of the fragments were cut from the gels and 
purified with QIAquick gel extraction kit.  
The 5 purified fragments were ligated with T4 DNA ligase at 16°C overnight. The 
ligation products were then purified with phenol/chloroform method, and detected 
by electrophoresis on 0.4% agarose gels to confirm the quality of ligation products. 
The purified ligation products was used for in vitro transcription. 
2.9.2. In vitro transcription and electroporation 
The ligation products were in vitro transcribed into full-length RNA using the 
mMessage mMachine T7 kit (Ambion) according to the manufacturer’s 
instructions. Briefly, 30 µl of transcription reaction with a 1:1 ratio of GTP to cap 
analog was sequentially incubated at 40.5°C for 25 min, 37.5°C for 50 min, 40.5°C 
25 min and 37.5°C for 20 min.   
N transcripts were in vitro transcribed with same methods. Linearized pKTO-
IBV N containing IBV N gene and the 3’-UTR region was used as templates. A 
1:2 ratio of GTP to cap analog was used for the transcription of IBV N gene.  
  59 
2.9.3. Introduction of in vitro synthesized transcripts into Vero cells by 
electroporation  
After the full-length RNA and N transcripts were synthesized, the transcription 
products were treated with DNase I and purified with phenol/chloroform methods. 
Vero cells at 90% confluency were trypsinized, washed with PBS, and re-
suspended in PBS. Purified RNA transcripts were added to Vero cell suspension in 
a 4 mm electroporation cuvette (Bio-Rad), and electroporated with one pulse at 
450 V, 50 µF with a Bio-Rad Gene Pulser II electroporator. The electroporated 
Vero cells were cultured overnight in 1% FBS containing MEM in aa six-well 
plate and further cultured in MEM without FBS. 
2.9.4. IBV plaque infectivity assay 
Confluent Vero cells in 6 well plates (IWAKI) were infected with 100 µl of 
100-fold diluted virus stock. After 1 h of incubation, cells were washed twice with 
PBS and cultured in 2 ml DMEM containing 1% carboxymethylcellulose (Sigma) 
and 1% FBS. After 4 days of incubation, the cells were fixed with 4% 
paraformaldehyde for 15 min, and visualized by staining the intact cells with 0.1% 
toluidine blue (Sigma) for 30 min. The yield of virus was calculated in terms of 
plaque-forming unit (PFU) per ml.  
2.9.5 Growth curve of the recombinant viruses on Vero cells 
Virus infected cells were freezed/thawed three times to make virus stock 24 
hours after virus infection. These virus stocks were used to infect Vero cells. 
Briefly, Confluent Vero cells on 6-well plates were infected with wild-type and 
recombinant IBV, and harvested at different time points after virus infection. The 
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50% tissue culture infection dose (TCID50) of each virus strain was calculated 
after infecting 5 wells of Vero cells on 96-well plates with 10-fold serial dilution of 
each viral stock. 
2.9.6. Virus purification  
Cells in T-75 Flask were washed once with PBS and infected with IBV at a 
MOI of 10. After incubation for 90 min, the inoculum was replaced with 12 ml of 
DMEM. At 18 h post-infection the supernatant was collected and clarified by 
centrifugation at 450 × g for 15 min. IBV particles were partially purified by 
ultracentrifugation on a 20% sucrose cushion in a Beckman SW28 rotor at 75,000 
× g for 3 h. The pellet was resuspended in 1 ml TNE (25 mM Tris-HCl pH 7.5, 150 
mM NaCl, 5 mM EDTA) and further applied on a discoutinous sucrose gradient of 
20 to 60% sucrose. The samples were centrifuged at 27,000 rpm in an SW41 rotor 
(Beckman) for 18 h at 4°C. Subsequently, 6 fractions were collected. Each 
fraction was analyzed with Western blotting using anti-M protein antibody. The 
fraction 8 and 9 were diluted in TNE and pelleted through a 20% sucrose cushion 
at 36,000 rpm for 2 h at 4°C. The purified pellet was stored at -80°C until use.   
2.9.7 Virion-like-particles preparation 
SARS-CoV VLPs were produced using a modification of a previously 
described method. Briefly, culture medium was harvested around 36 hours after 
transfection, and clarified by centrifugation at 5,000 g for 10 min. The supernatant 
was layered over a 20% sucrose buffer (20% sucrose, 20 mM HEPES, pH 7.4, 
0.1% bovine serum albumin [BSA]) and centrifuged at 27,000 rpm in an SW41 
rotor (Beckman) for 2 h at 4°C. VLPs collected in the pellet were resuspended in 
50μl of phosphate-buffered saline for further study. The VLP suspension was 
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further loaded on a continuous sucrose gradient consisting of 25% - 55% sucrose in 
20 mM HEPES (pH 7.4) and 0.1% BSA and then centrifuged in the SW61 rotor at 
36,000 rpm for 12 h at 4°C. Fractions were analyzed for the presence of SARS-
CoV structural proteins by Western blotting. 
  62 
Table 2.1 Primer list 
__________________________________________________________________ 
Name                    Sequence 
IFNb F:  5'-AAACTCATGAGCAGTCTGCA-3' 
IFNb R:  5'-AGGAGATCTTCAGTTTCGGAGG-3' 
 
KLF4 F:  5'-AACCCACACAGGTGAGAA-3' 
KLF4 R:  5'-TACGGTAGTGCCTGGTCAGTTC-3' 
 
ISGF3g F: 5'-AAGTAGACTCATTCTTCACGATTGAC-5' 
ISGF3g R:  5'-AGCCAGTGTGTGCGAGGATT -3' 
 
IFIT4 F:  5'-AACTACGCCTGGGTCTACTATCACTT-3' 
IFIT4 R:  5'-GCCCTTTCATTTCTTCCACAC-3' 
 
GAPDH F:  5'-GACAACTTTGGTATCGTGGAA-3' 
GAPDH R:  5'-CCAGGAAATGAGCTTGACA-3' 
 
S6 F:  5'-CGGGTCTCACACATAACAAAAACTTAACAAA 
TACGGACGATGTTTCATCTTGTTGAC-3' 
S6 R:   5'-CGGGTCTCACATTATGGATAATCTAACTC-3' 
 
Luc F:   5'-CGGGTCTCTGATGGAAGACGCCAAAAACAT-3'  
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Figure 2.1 Strategy for the assembly of an IBV infectious cDNA clone  
The genome of IBV contains regions coding for non-structural proteins, e 
structural proteins S, E, M, and N, accessory proteins 3a, 3b, 5a, and 5b, and the 
5’- and 3’-UTR. The genome was divided into five fragments to facilitate 
modification. The T7 promoter sequence was inserted at the 5’-end of fragment A, 
and the 30 As were inserted at the 3’-end of fragment E.  
Plasmids were modified to delete/insert specific genes and then digested with 
enzymes BsmBI or BsaI. The five fragments were gel purified after digestion, and 
ligated to get the full length DNA. The ligation products were then in vitro 
transcribed into RNA and electroporated into Vero cells to recover viruses. 
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CHAPTER 3. BIOCHEMICAL AND FUNCTIONAL 
CHARACTERIZATION OF SARS-COV ORF9B  
  66 
3.1 SARS-CoV accessory protein 9b is translated via ribosome leaky scanning 
3.1.1 Introduction 
Despite extensive studies on SARS-CoV, there is still limited information 
on its accessory protein, 9b. Antibodies against 9b have been detected in SARS 
patients (Qiu et al., 2005), and analysis of the context of the translation initiation 
sites suggest 9b may be translated via ribosomal leaky scanning. Both 9b and N are 
translated from the same subgenomic RNA (sgRNA) at different open reading 
frames. According to the analysis at their respective translation initiation sites, the 
two sites for N and 9b are very close, and there are only 7 nucleosides between 
them. It has been reported that GCCGCCRCCAUGG is preferred in higher 
eukaryotes (Kozak, 1981, 1984a and b, 1987) (numbering begins with the A of 
AUG codon as position +1; nucleotides 5’ to that site are assigned negative 
numbers and R is a purine). Site-directed mutagenesis data have confirmed that 
G
+4
, as well as each of the consensus nucleotides from position -1 to -6, is very 
important (Kozak, 1986 and Kozak, 1987).  
Accordingly, the initiation site for 9b is quite strong while the one for N is 
rather weak (Snijder et al., 2003). Furthermore, studies on other coronaviruses have 
shown that the Internal ORF (I, in abreviation), a 9b counterpart in other 
coronaviruses, is hidden in the Nucleocapsid gene and translated via ribosomal 
leaky scanning. In the case of BCV, I protein has been reported to undergo 
translation via ribosome leaky scanning (Senanayake et al., 1997). For MHV, the 
Internal ORF was translated via ribosomal leaky scanning mechanism as well 
(Fisher et al., 1997). These analyses and reports thus led to the hypothesis that 9b is 
translated via ribosome leaky scanning.  
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3.1.2 SARS-CoV protein 9b is expressed from sgRNA 9 both in vitro and in 
intact cells 
Before looking into the translation mechanism, we first wanted to confirm 
if protein 9b is truly expressed by sgRNA 9. To test whether both N and 9b protein 
are encoded by sgRNA 9, we examined the translation products of sgRNA 9 using 
a coupled in vitro transcription and translation system, as well as in intact cells. A 
cDNA fragment that incorporates sgRNA 9 was inserted into a pKT0 vector, and 
three more mutant constructs were engineered based on the original plasmid pN. 
Construct pN contains the original N gene, including both ORF N and ORF9b. 
Construct pN9b also contains the N gene, but ORF9b is abolished through 
mutation of the translation initiation codon from ATG to GAG. Construct pF-9b 
contains the 9b gene with a Flag tag at the N-terminus to facilitate detection. In 
addition, construct pF-N was made with the addition of a Flag tag to the N protein. 
At the same time, the translation initiation site was directly put in the context of 
pKT0, such that the translation initiation site would be a strong one.   
All plasmids were first expressed in vitro using a coupled in vitro 
transcription and translation system (Promega). The translation products were 
radio-labeled with (
35
S)-methionine and examined after SDS-PAGE. Translation of 
pN led to the detection of two dominant bands with molecular weights around 10 
kiloDaltons (kDa) and 50 kDa, respectively, in similar quantities (Fig. 3.1a, lane 
11). In contrast, the 10 kDa band was not detected from the translation of pNΔ9b 
(Fig. 3.1a, lane 12). These two bands may represent protein 9b and protein N, 
respectively. Translation of pF-9b and pF-N led to the detection of the Flag-tagged 
9b and N proteins (Fig. 3.1a, lanes 9 and 10), which are slightly larger in size than 
the non-tagged proteins. The 10 kDa band was not detected from pF-N products. 
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This may be due to the change in the context of the first translation initiation site. 
The nucleotide sequence surrounding the first translation initiation is from the 
plasmid and, as such, strengthens the translation initiation site. Moreover, the 
nucleotide sequence encoding a Flag tag added additional distance between the 
first translation initiation site and the second one, which makes the second one less 
preferable. 
To further confirm the identities of these products, the proteins from the in 
vitro transcription and translation system were immunoprecipitated with antibodies 
against protein 9b or protein N, which were raised from rabbits in our laboratory, 
and detected using similar methods as described above. Briefly, the translation 
product was incubated with appropriate serum containing specific antibodies for 2 
h at room temperature with shaking before incubation with protein A agarose beads 
for 2 h at room temperature. After washing with RIPA buffer three times, the beads 
were incubated with 2 × Laemmli’s sample buffer and boiled for 5 min before they 
were analyzed in SDS-PAGE. As shown in Figure 3.1a, the 50 kDa band was 
pulled down by anti-N antibodies (lanes 5 and 6) and the 10 kDa band was pulled 
down by anti-9b antibodies (lanes 2 and 3). These results confirmed that sgRNA 9 
is bicistronic, and that both N and 9b are expressed from sgRNA 9 in vitro.  
Examination of the expression products from sgRNA 9 in intact cells was 
then carried out by transfection of the constructs pNΔ9b, pN and pF-9b into H1299 
cells and analyzed by Western blotting with anti-N and anti-9b antibodies. As 
described above, cells grown on dishes were infected with a recombinant vaccinia 
virus (vTF7-3) that expresses T7 RNA polymerase at a MOI of 1. Two hours later, 
cells were transfected with the given plasmid DNA mixed with Effectene, 
according to the instructions of the manufacturer (QIAGEN Inc.). Cells were 
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harvested at 24 h post transfection. Cell lysate was then examined with 
immunoblotting after SDS-PAGE. As shown in Figure 3.1b, the Flag-tagged 9b 
was detected from cells transfected with pF-9b (lane 1), and 9b was detected from 
cells transfected with pN (lane 2), but not from cells transfected with pNΔ9b (lane 
3). The N protein was detected from cells transfected with both pN and pNΔ9b 
(Fig. 3.1b, lanes 2 and 3). These results demonstrate that both 9b and N are 
expressed from sgRNA 9 in intact cells.  
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Figure 3.1 SARS-CoV protein 9b is expressed in in vitro translation system and in 
intact cells 
A. Translation products of the plasmids from in vitro transcription and translation 
system. Plasmid DNA was translated in rabbit reticulocyte lysates (RRL) using a 
transcription coupled-translation (TnT) system (Promega). Circularized plasmid 
DNA was incubated with RRL together with RNase inhibitor, minus-methionine 
amino acids mix in the presence of 50 µCi of [
35
S]-methionine. The translation 
products were separated with SDS-PAGE. The Gels were dried under vacuum and 
exposed to X-ray film for autoradiography at -80ºC. Lanes 9-12 show the 
translation products of pKT0-f9b, pKT0-fN, pKT0-N, pKT0-N Δ9b. Lanes 1-4 
show the products immunoprecipitated with antibodies against 9b. Lanes 5-7 show 
the products immunoprecipitated with antibodies against N.  
B. Translation products of the plasmids in H1299 cells. H1299 cells were infected 
with vaccinia/T7 virus for 1 h, and were then transfected with specific plasmids. 
Cells were harvested 24 hours later. Cell lysate was separated with SDS-PAGE, 
gels were electroblotted to a PVDF membrane, and detected with specific 
antibodies. Antibodies against SARS-CoV N were used in upper column, and 
antibodies against SARS-CoV 9b were used in bottom column. Lanes 1-3 show the 
translation products of pKT0-f9b, pKT0-N, pKT0-N Δ9b in H1299 cells.  
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3.1.3 SARS-CoV protein 9b is translated via ribosomal leaky scanning 
The mechanism that controls the translation of 9b from the bicistronic 
sgRNA 9 was then studied by introducing mutations in the nucleotide sequences 
flanking the AUG codons for both N and 9b. As discussed above, the optimal 
context for the recognition of AUG as an initiation codon is GCCRCCaugG 
(Kozak, 2002), and the purine (R) at position -3 and the G at position +4 are highly 
conserved. To avoid cell death caused by Vaccinia virus, the plasmid pXJ40, which 
contains a CMV promoter, was used as a vector for sgRNA9. Three mutations 
were constructed based on pN(9bH), as shown in Figure 3.2a. In the original 
construct pN(9bH), a HA-tag was fused to the C-terminus of 9b to facilitate 
detection, without changing the reading frame of N.  In the pN(9bH)-m1 construct, 
A was replaced by C at the -3 position of the AUG codon for N, which made the 
translation initiation site even less favorable. Site-directed mutagenesis PCR was 
achieved using the QuikChange site-directed mutagenesis kit (Strategene). In 
pN(9bH)-m2, the ATG codon for N was changed to TTG, which abolished the 
translation initiation of N (Fig. 3.2a). In pN(9bH)-m3, T and A were both replaced 
with C at the -1 and -2 positions of 9b (Fig. 3.2a). If 9b were to be translated via 
ribosome leaky scanning, less N and more 9b would be translated from m1, no N 
and much more 9b would be translated from m2, while a similar amount of N and a 
slightly larger amount of 9b would be expected from m3. 
Specific plasmids were transfected into H1299 cells without Vaccinia virus 
infection. Cells were harvested 36 hours post-transfection and total cell lysates 
were examined with Western blotting, using anti-N and anti-HA antibodies. 
Compared with the original pN(9bH), transfection of pN(9bH)-m1 showed a 
slightly lower expression of N protein with a significantly higher expression of 9b 
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(Fig 3.2b, lanes 2 and 3). Transfection of pN(9bH)-m2 showed no expression of N 
and an extremely high expression of 9b (Fig 3.2b, lane 4). Transfection of 
pN(9bH)-m3 showed a slightly higher expression of both N and 9b, compared to 
the original pN(9bH) (Fig 3.2b, lane 5). In general, the translation profile of these 
constructs follow the prediction based on ribosomal leaky scanning. However, it 
was also noted that the expression level of N from m3 is also slightly higher 
compared with that of the original construct. The reason for this is unknown. In 
general, these data together support the hypothesis that protein 9b is translated via 
ribosome leaky scanning.  
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Figure 3.2 Protein 9b is expressed via ribosomal leaky scanning mechanism  
A. Three mutants were constructed with Site-directed mutagenesis PCR. In the m1 
construct, C replaced A at the -3 position of the AUG codon for N. In m2, the ATG 
for N is changed to TTG. In m3, T and A are replaced with C and C at the -1 and -2 
positions of 9b respectively. As indicated, HA tag was fused to the C-terminal of 
9b. 
B. The expression of N and 9b in the wild-type and mutant constructs in H1299 
cells. H1299 cells were infected with vaccinia/T7 virus for 1 h, and were then 
transfected with specific plasmids. Cells were harvested 24 hours later. Cell lysate 
was separated with SDS-PAGE. Gels were electroblotted to a PVDF membrane, 
and detected with specific antibodies. Antibodies against SARS-CoV N were used 
in upper column, antibodies against HA were used in middle column, and 
antibodies against Tubulin were used in the bottom column. 
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3.2 SARS-CoV protein 9b facilitates virion assembly 
3.2.1 Introduction 
The virions of coronaviruses (CoVs) are pleiomorphic, with a roughly 
spherical structure that is brought about by cooperation among a set of structural 
proteins and a membranous envelope acquired from the endoplasmic reticulum–
Golgi intermediate compartment (ERGIC). Three integral membrane proteins 
reside in the envelope. The most salient of these is the spike glycoprotein (S), 
which mediates receptor attachment and fusion of the viral and host cell 
membranes. The membrane protein (M) is the most abundant virion component. 
The third constituent is the envelope protein (E), which, although minor in both 
size and quantity, plays a decisive role is envelope formation. Finally, interior to 
the envelope, monomers of the nucleocapsid protein (N) wrap the genome into a 
helical structure. Among these structural proteins, the M protein has been shown to 
be the central organizer of CoV assembly, as M adapts a region of membrane for 
virus assembly and captures other structural proteins at the budding site.   
Virus assembly begins with the formation of a helical nucleocapsid, which 
associates with smooth membranes belonging to the ER-Golgi intermediate 
compartment (ERGIC) that constitute the budding compartment for coronaviruses 
(Krijnse-Locker et al., 1994). The coronavirus N protein has been shown to bind 
viral RNAs in sequence-specific and non-sequence-specific manners (Cologna et 
al., 2000; Robbins et al., 1986; Stohlman et al., 1988b). Interactions between M 
and other structural proteins, including N, then bring the rest of the envelope 
components to the nucleocapsid to form virions.  
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M and E proteins are necessary and sufficient for the formation and release of 
VLPs in all three groups of CoVs: MHV, BCoV and SARS-CoV (group 2), TGEV 
(group 1), and IBV (group 3). As aptly described by their name, virion-like 
particles (VLPs) have morphology and gradient properties similar to those of 
genuine virions. Although they also have envelope structures, the envelope 
structure of VLPs may be lacking in several proteins. The only apparent exceptions 
are those from SARS-CoV. It has been reported that M protein and N protein were 
necessary and sufficient for VLP formation for SARS-CoV (Huang et al., 2004). 
Since the SARS-CoV ORF9b has been earlier shown as hidden in the N gene, we 
suspect that ORF9b may play roles in this assembly process as well.  
Previous reports on SARS-CoV ORF9b have also suggested that protein 9b 
may facilitate virion assembly. The crystal structure of protein 9b has been solved 
(Meier et. al. 2006). It has a dimeric tent like structure with an amphipathic surface, 
and a central hydrophobic cavity. In the same report, protein 9b was also found to 
aggregate into some unknown particles inside the cells. It is known that during 
virion assembly, the structural proteins and genomic RNA aggregate at ERGIC to 
form virions. The sub cellular localization and its structure thus led to the 
hypothesis that protein 9b may play a role in the virion assembly process. 
3.2.2 Protein 9b interacts with structural proteins E and M 
To gain insights into the functions of 9b, especially – as suggested by 
previous structural studies – that in virion assembly, the potential interaction 
between 9b and other structural proteins was tested by co-immunoprecipitation. 
The Flag-tagged 9b was co-expressed with either E or M in H1299 cells, and anti-
Flag antibodies were used to pull down the 9b protein. Specific antibodies against 
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E and M were used to detect given structural proteins. As shown in Figure 3.3, 
efficient expression of E, M and 9b was observed in cells expressing E and M 
either individually or together with 9b. According to previous studies, E and M are 
key components in virion assembly for Coronaviruses.  
Immunoprecipitation of the Flag-tagged 9b with anti-Flag antibodies 
showed efficient co-precipitation of E in cells co-expressing 9b and E (Fig. 3.3, 
lane 11). Co-precipitation of M also observed in cells co-expressing 9b and M, 
albeit with much reduced efficiency (Fig. 3.3). The co-immunoprecipitation of 9b 
with the two structural proteins demonstrates that 9b interacts with structural 
proteins E and M.  
 The observation here suggests that 9b may facilitate virion assembly via its 
interactions with E and M. 
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Figure 3.3 SARS CoV protein 9b interacts with structural proteins E and M  
a. H1299 cells were infected with vaccinia/T7 virus for 1 h, and were then 
transfected with specific plasmids. Cells were harvested 24 hours later. Cells were 
lysed with lysis buffer. Cell debris was removed and the supernatant was incubated 
with antibodies against Flag. Protein A agarose beads were then added into the 
mixture. After washing with lysis buffer, the beads were incubated with 
2×Laemmli’s sample buffer and ready to be analysed with western blotting. Cell 
lysate and Immunoprecipitation products were separated with SDS-PAGE, gels 
were electroblotted to a polyvinylidene difluoride (PVDF) membrane, and detected 
with specific antibodies. Antibodies against SARS-CoV M were used in the upper 
column, antibodies against Flag were used in bottom column. Lanes 1-3 show the 
co-expression M and vector, M and flag9b, vector and flag9b, respectively. Lanes 
3-6 show the product immunoprecipitated with flag antibodies.  
 
b. H1299 cells were infected with vaccinia/T7 virus for 1 h, and were then 
transfected with specific plasmids. Cells were harvested 24 hours later. Cells were 
lysed with lysis buffer. Cell debris was removed and the supernantant was 
incubated with antibodies against Flag. Protein A-agarose beads were then added 
into the mixture. After washing with lysis buffer, the beads were incubated with 
2×Laemmli’s sample buffer and ready to be analysed with western blotting. Cell 
lysate and Immunoprecipitation products were separated with SDS-PAGE, gels 
were electroblotted to polyvinylidene difluoride (PVDF) membrane, and detected 
with specific antibodies. Antibodies against SARS-CoV E were used in upper 
column, antibodies against Flag were used in the bottom column.Lanes 1-3 show 
the co-expression E and vector, E and flag9b, vector and E. Lanes 3-6 show the 
product immunoprecipitated with flag antibodies.  
  81 
3.2.3 Protein 9b overlaps with lysosome and endosome markers 
 It was previously reported that protein 9b form particles in cells (Meier et. 
al. 2006); however, the origin and properties of these particles are not clear. HA-
tagged 9b was expressed in cells, and then treated for observation under confocal 
microscope. Sequences for Hemagglutinin(HA) were inserted to produce a fusion 
pretein with HA tag at the C-terminal of ORF9b. Markers for the endosome and 
lysosome, respectively, were selected to identify the localization of 9b particles. 
EEA1 is an early endosome-associated protein, and LAMP-1 is Lysosome-
associated membrane protein. As observed in Figure 3.4, the two markers were 
detected in these 9b particles when 9b was transiently expressed in cells. This 
observation suggests that the particles could have originated from different sources, 
including the endosome and lysosome.  
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Figure 3.4 Protein 9b overlaps with lysosome and endosome markers 
H1299 cells were transfected with pXJ40-9bHA plasmids. Cells were fixed with 
4% paraformaldehyde, permeabilized with 0.2% Triton
 
X-100 and washed with 
PBS. Cells were then immune-labeled with antibodies against HA and antibodies 
against EEA1 (top column), or with antibodies against HA and antibodies against 
LAMP1 (bottom column). The cells were then washed with PBS and incubated 
with goat IgG conjugated with Alexa Fluor 488 / Alexa Fluor 594. The cells were 
mounted with glass coverslips using a mounting medium (DAKO). Images were 
collected with a META 510 confocal laser-scanning microscope (Zeiss).  
The left row shows the subcellular localization of protein 9bHA in H1299 cells. 
The middle row shows the subcellular localization of protein EEA1 and protein 
LAMP1 in H1299 cells. The right row shows the merge of previous rows. 
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3.2.4 Protein 9b is involved in the formation of VLP with M 
Since E and M are major components of the virions and are, together, 
sufficient for the formation of VLP, the observation that the two proteins could 
interact with 9b prompted us to study the involvement of 9b in virion assembly 
using the VLP system. M was co-expressed either with E, Flag-tagged 9b, N, N9b 
or an empty vector as negative control in H1299 cells, and the VLPs secreted into 
the media were collected by ultracentrifugation with sucrose cushioning. The 
expression of these proteins in total cell lysates was analyzed with appropriate 
antibodies and shown in Figure 3.5. The M protein was robustly expressed at 
similar amounts either on its own or together with one of these proteins (Fig. 3.5, 
top panel).  When cells were co-transfected with pN and pNΔ9b, respectively, 
efficient expression of N was observed from both constructs (Fig. 3.5, second 
panel, lanes 4 and 5).  However, 9b was expressed only in cells co-transfected with 
pN (Fig. 3.5, fifth panel, lane 4).  In cells co-expressing M+E or M+Flag tagged 
9b, efficient expression of E and 9b was also observed (Fig. 3.5, third panel, lane 1 
and fourth panel, lane 3).  
The formation of VLPs in cells co-expressing M and one of the four 
constructs was then analyzed by collecting the culture media from the transfected 
cells, pelleting through 20% sucrose cushion at 27000 rpm ultracentrifugation and 
detected by Western blotting with specific antibodies. M protein was used as an 
indicator for VLP formation, because M is major component in VLPs. In cells co-
expressing either M+E or M+Flag tagged 9b, significant amounts of M protein 
were detected in the culture media (Fig. 3.5, bottom panel, lanes 1 and 3), 
suggesting the efficient formation and release of VLPs in these transfected cells. In 
cells co-expressing M+N, a significant amount of M protein was also detected in 
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the culture media (Fig. 3.5, bottom panel, lane 4). However, minor amounts of M 
protein were detected in the culture media collected from cells transfected with M 
alone or M+NΔ9b (Fig. 3.5, bottom panel, lanes 2 and 5). As trace amounts of 
actin were also detected in these samples (Fig. 3.5, bottom panel), the presence of 
minor amounts of M protein in the culture media from these two transfected cells 
may reflect the contamination of culture media with cell lysates from the dead 
cells. In conclusion, protein 9b is involved in the formation and release of VLPs, 
and the co-expression of 9b and M is sufficient to form VLP. 
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Figure 3.5 Protein 9b functions during virion assembly and release  
H1299 cells were infected with vaccinia/T7 virus for 1 h, and were then transfected 
with specific plasmids. Cells were harvested 36 hours post transfection. Virion like 
particles from culture medium was collected as described in chapter 2.9.7. Briefly, 
medium was clarified by centrifugation at 5,000 g for 10 min. The supernatant was 
layered over a 20% sucrose buffer and centrifuged at 27,000 rpm in an SW41 rotor 
(Beckman) for 2 h at 4°C. VLPs collected in the pellet were resuspended in protein 
loading buffer and analysed with western blotting. 
Samples of cell lysate and VLPs were separated with SDS-PAGE. Gels were 
electroblotted to polyvinylidene difluoride (PVDF) membrane, and detected with 
specific antibodies. Antibodies against SARS-CoV M, E, N, flag9b, 9b and actin  
were used in columns as indicated. 
The upper columns show the proteins from total cell lysate, while the bottom 
columns show the proteins from VLPs purified from medium. M is used to indicate 
amount of VLPs, because M is the most abundant structural protein in VLPs. Lanes 
1-5 show the co-expression of M and E, M and empty vector, M and flag9b, M and 
N, M and N∆9b.  
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3.2.5 Protein 9b is incorporated into VLPs 
In addition to the M protein, N, E, Flag-tagged 9b and 9b proteins were also 
detected from the culture media in cells co-expressing M+E, M+Flag tagged 9b, 
and M+9b, respectively (Fig. 3.6a). N and E are well-established structural 
proteins, but protein 9b is previously considered as an accessory protein. The 
detection of 9b in VLPs suggests that 9b may be also incorporated into VLPs as a 
structural protein.   
To test for the existence of protein 9b in VLPs, VLPs formed from cells co-
expressing M+E+Flag-tagged 9b were purified by ultracentrifugation through a 20-
55% continuous sucrose gradient. Western blotting analysis of six fractions 
collected showed the presence of a majority of E and the Flag-tagged 9b proteins in 
fraction 4 (Fig. 3.6b, top and middle panels). In addition, minor amounts of the 
proteins were also detected in fraction 3 (Fig. 3.6b, top and middle panels). 
Analysis of the same fractions by Western blotting with anti-tubulin antibodies did 
not detect tubulin (Fig. 3.6b, bottom panel), indicating the relative purity of VLPs. 
These data showed that VLPs were concentrated in the 4
th
 fraction, and the co-
fractionation of 9b with another VLP component further supports the hypothesis 
that protein 9b is incorporated into VLPs as structural protein.  
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Figure 3.6 Protein 9b is co-purified with other VLP components  
H1299 cells were infected with vaccinia/T7 virus for 1 h, and were then transfected 
with specific plasmids. Cells were harvested 36 hours post transfection. Virion like 
particles from culture medium was collected as described in chapter 2.9.7. Briefly, 
medium was clarified by centrifugation at 5,000 g for 10 min. The supernatant was 
layered over a 20% sucrose buffer and centrifuged at 27,000 rpm in an SW41 rotor 
(Beckman) for 2 h at 4°C. VLPs collected in the pellet were resuspended in protein 
loading buffer and analysed with western blotting. 
 
A. Samples of VLPs from medium were separated with SDS-PAGE. Gels were 
electroblotted to polyvinylidene difluoride (PVDF) membrane, and detected with 
specific antibodies. Antibodies against SARS-CoV M, E, N, flag9b, 9b and actin  
were used in columns as indicated. Lanes 1-5 show the viral proteins from medium 
of H1299 cells transfected with M and E, M and empty vector, M and flag9b, M 
and N, Mand N∆9b.  
B. The VLP suspension was further loaded on a continuous sucrose gradient 
consisting of 25% - 55% sucrose in 20 mM HEPES (pH 7.4) and 0.1% BSA and 
then centrifuged in the SW61 rotor at 36,000 rpm for 12 h at 4°C. Fractions were 
analyzed for the presence of SARS-CoV structural proteins by Western blotting.  
Samples of these fractions were separated with SDS-PAGE. Gels were 
electroblotted to polyvinylidene difluoride (PVDF) membrane, and detected with 
specific antibodies. Antibodies against SARS-CoV M, E, N, flag9b, 9b and actin 
were used in columns as indicated. Lanes from 1-6 show the VLP purified with 
continuous sucrose gradient.  
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3.2.6 Lipid rafts are required for virus assembly 
3.2.6.1 Introduction 
Lipid rafts are cholesterol- and sphingolipid-enriched microdomains found 
in cell membranes. They are mainly composed of cholesterol, (glyco)sphingolipids 
and (glycero)phospholipids, with a high degree of saturation in their fatty-acid 
chains. The tight interaction between these components provides the basis of their 
packing and rigidity, which leads to a phase separation (Simons and Ikonen, 1997). 
The lipid raft size in vivo has been estimated to be 25–700 nm by using FRET and 
single-molecule-tracking microscopy. The size, arrangement and movement of 
lipid rafts are dynamic and can be found in localized cellular structures, such as 
filipodia and cell adhesion points (Chazal and Gerlier, 2003; Hawkes and Mak, 
2006). 
 Many viruses require lipid rafts in replication stages such as entry, 
assembly and release. It has been reported that several viruses, including influenza 
virus, HIV, MLV (murine leukaemia virus), measles virus and Ebola virus, have 
their glycoproteins associated with host-cell membrane rafts for virus entry 
(Scheiffele et al., 1997; Manie et al., 2000; Vincent et al., 2000; Pickl et al., 2001; 
Bavari et al., 2002). SARS-CoV receptors are also located in lipid rafts, and the 
productive entry of the SARS-CoV pseudovirus into the host cell requires the 
presence of intact and functional lipid rafts (Lu et al., 2008). Many viruses, 
including HIV-1, influenza virus, measles virus, Ebola virus and possibly Sendai 
virus, use lipid rafts as assembly platforms (Luo et al., 2008). When overexpressed, 
SARS-CoV E and IBV E proteins were reported to be mainly in lipid rafts (Yuan et 
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al., 2006). These earlier studies suggest that lipid rafts may be required by 
coronavirus for virion assembly. 
3.2.6.2 Lipid rafts are required for virus assembly 
Here, we continued to explore whether lipid rafts are employed in virion 
assembly for coronavirus as well. Cells were infected by IBV at MOI of 1, after 
which methyl-ß-cyclodextrin (MßCD; 8 mM) or PBS were added into the medium, 
and the lipid rafts were isolated 24 hours post infection. Cells were lysed, and 
centrifugated with
 
discontinuous layers of 35% and 5% sucrose.After 
centrifugation fractions were sequentially collected starting from
 
the top to the 
bottom of the tube after centrifugation. Proteins in each fraction were resolved by 
SDS-PAGE and detected by Western analysis with the appropriate primary and 
secondary antibodies. IBV protein E, N, S and Nsp 12, and host protein Caveolin 1 
from fractions were examined.  
As showed in Fig. 3.7, IBV structural protein N, E and S, and Caveolin 1 
were detected at significant amounts in fraction 4 from cells infected with IBV, 
while IBV Nsp 12 was not detected at the lipid raft fraction. In MßCD-treated cells, 
both IBV E and Nsp 12 were not detected in fraction 4, although small amounts of 
Caveolin 1, IBV N and IBV S were detected. Compared with untreated cells, the 
accumulation of virus structural proteins in MßCD-treated cells was greatly 
lowered. This result shows that IBV structural proteins accumulate on lipid rafts, 
and this accumulation is interrupted when cells were treated with MßCD.  
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Figure 3.7 Proteins in lipid rafts from H1299 cells infected with IBV 
H1299 cells were first infected with IBV at MOI of 1, before 8mM MßCD or PBS 
was added into medium, and the lipid rafts were isolated 24 hours post infection. 
Cells were lysed and treated with Triton X-100. The mixture was overlaid with
 
discontinuous layers of 35% and 5% sucrose. Gradients were resolved
 
by 
centrifugation in a Beckman SW41 rotor at 160,030 x g (36,000
 
rpm) for 18 h at 
4°C. Fractions were sequentially collected starting from
 
the top to the bottom of the 
tube after centrifugation. Proteins in each fraction were resolved by SDS-PAGE. 
Gels were electroblotted to polyvinylidene difluoride (PVDF) membrane, and 
detected with specific antibodies. Antibodies against IBV E, N, S and NSP 12, and 
Caveolin 1 were used in columns as indicated. 
This work was completed in cooperation with Ms. Law Yin Chern. 
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We continued to use the VLP system to study the possible functions of lipid 
rafts in SARS-CoV virion assembly. SARS-CoV E and M proteins were co-
expressed in MβCD treated / untreated H1299 cells, and the release of VLPs in 
medium weas examined as described earlier. MβCD is known to specifically 
prevent lipid raft formation because it remove cholesterol from cultured cells. As 
shown in Figure 3.8, M and E was detected in the supernatant from cells that were 
treated with MβCD, while these two proteins were detected in the medium from 
MβCD untreated cells. This observation demonstrated that VLPs could not be 
released once the formation of lipid rafts was disrupted. Lipid rafts are therefore 
required by coronavirus in virion assembly and release. 
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Figure 3.8 Lipid raft is required for virus assembly 
H1299 cells were infected with vaccinia/T7 virus for 1 h, and were then transfected 
with specific plasmids using lipofectamine 2000 (Invitrogen). The transfection 
reagents were removed 6 hours later, and fresh medium with FBS was added to 
maintain cell growth. MßCD (8 mM ) was added for MßCD treated cells. Cells 
were harvested 36 hours post transfection. Total cell lysate was analyzed with 
western blotting later. 
Virion like particles from culture medium was collected as described earlier. 
Briefly, medium was clarified by centrifugation at 5,000 g for 10 min. The 
supernatant was layered over a 20% sucrose buffer and centrifuged at 36,000 rpm 
in an SW41 rotor (Beckman) for 2 h at 4°C. VLPs collected in the pellet were 
resuspended in protein loading buffer and analysed with western blotting. 
Samples of cell lysate and VLPs were separated with SDS-PAGE. Gels were 
electroblotted to polyvinylidene difluoride (PVDF) membrane, and detected with 
specific antibodies. Antibodies against SARS-CoV M, E, and tubulin were used in 
columns as indicated. 
A. Lanes show the expression level of M, E and tubulin in cells that are transfected 
with specific plasmids. These cells were either treated or untreated with MβCD.  
B. Lanes show the existence of proteins M, E and tubulin in the medium of cells 
transfected with specific plasmids. These cells were either treated with MβCD or 
untreated with MβCD. 
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3.2.6.3 Snapin is required for efficient virus replication 
Snapin is highly enriched in lipid rafts. Snapin was originally identified as a 
SNAP25 interaction protein and described to be an exclusively neuronal protein 
that regulates the association of the calcium sensor synaptotagmin with the SNARE 
complex (Ilardi et al., 1999). Further studies have also shown that Snapin interacts 
with SNAP23 (Buxton et al., 2003) and exists in the biogenesis of lysosome-related 
complex-1 (BLOC-1) (Starcevic et al., 2004). In general, Snapin functions in 
protein transport and vesicle exocytosis (Ruder et al., 2005). 
To examine whether Snapin affects coronavirus replication, we knocked 
down Snapin in H1299 cell, infected the cells with IBV, and checked the 
replication efficiency of viruses. The amount of Snapin at the RNA level and 
protein level was examined using RT-PCR and western blotting. As shown in 
Figure 3.9 the knockdown of Snapin was successful, as the amount of Snapin RNA 
and Snapin protein is not detectable. IBV was used to infect cells knocked down 
with Snapin, and CPE was observed under the microscope. As Figure 3.10 shows, 
virus replication in cells was greatly affected when Snapin was knocked down.   
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Figure 3.9 Snapin is knocked down in H1299 cells  
Small interfering RNAs (siSnapin: 5'-TGCTGGATTCGGGAATTTA-3' 
siEGFP: 5'-GCAACGUGACCCUGAAGUUC-3') were purchased from 
Dharmafect (Dharmacon). Transfection of siRNA into H1299 cells grown to 60% 
confluence was performed using DharmaFECT transfection reagent (Dharmacon) 
according to the manufacturer’s instructions. siRNA solution in serum-free 
medium was mixed with DharmaFECT transfection reagent 2, also in serum-free 
medium of equal volume, mixed briefly and incubated at room temperature for 20 
min. Culture medium was then removed from the cells, and the transfection mix  
was added to them. Transfected cells are incubated at 37°C with 5% CO2 for 48 h 
(for mRNA analysis) or 72 h (for protein analysis). 
A. RT PCR results to show amount of Snapin at RNA level. Total RNA was 
extracted with Trizol according to manufacuturer’s instruction. Random primers 
were used for reverse transcription. Primers of Snapin and primers of GAPDH 
were used to detecte the amount of target genes in cDNA. 
B. Western blotting results to show amount of Snapin at protein level. Cell lysate 
were separated with SDS-PAGE. Gels were electroblotted to polyvinylidene 
difluoride (PVDF) membrane, and detected with specific antibodies. Antibodies 
against Snapin and tubulin were used in columns as indicated.  
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Figure 3.10 Replication efficiency of IBV in Snapin knock down cells  
Small interfering RNAs (siRNA) were purchased from Dharmafect (Dharmacon). 
Transfection of siRNA into H1299 cells grown to 60% confluence was performed 
using DharmaFECT transfection reagent (Dharmacon) according to the 
manufacturer’s instructions. siRNA solution in serum-free medium was mixed with 
DharmaFECT transfection reagent 2, also in serum-free medium of equal volume, 
mixed briefly and incubated at room temperature for 20 min. Culture medium was 
then removed from the cells, and the transfection mix added to them. Transfected 
cells are incubated at 37°C with 5% CO2. The experiments were performed in 
triplicates, and representative pictures are shown here.  
The cells were infected with IBV at MOI of 1 at 24 hours post transfection. The 
cells were incubated with IBV for 1 h, and then fresh medium with FBS was 
changed to maintain cell growth. Cells were observed under microscope at 0, 8, 16, 
24 and 32 hours post IBV infection. 
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 3.3 Discussion 
In this chapter, ORF9b has been illustrated to undergo translation via 
ribosomal leaky scanning, after the introduction of mutations to the context of the 
translation initiation sites.  When co-expressed with SARS CoV M and E proteins, 
ORF9b was incorporated into virion like particles. Co-expression of M and ORF9b 
leads to successful VLP formation and release. The pull-down assays also 
demonstrated the interaction of ORF9b with SARS CoV structural proteins E and 
M. Lipid rafts are required by coronaviruses for efficient VLP assembly and 
release. Snapin, which is enriched in lipid rafts, is required for efficient replication 
of IBV. 
3.3.1 SARS-CoV ORF9b is translated via ribosomal leaky scanning 
ORF9b is an internal ORF in the N gene-coding region on SARS-CoV 
bicistronic mRNA9. Coordinate proteins similar to SARS-CoV ORF9b exist at 
same position in other group II coronaviruses (Fischer et al., 1997, Lapps et al., 
1987 and Senanayake and Brian, 1997). These proteins are called “Internal” or “I” 
proteins because they are hidden in N gene coding region. Like other ORF I within 
the N gene from other coronaviruses, 9b is also translated via ribosomal leaky 
scanning. In previous reports, the BCoV I protein has been proven to translate via 
ribosomal leaky scanning as well (Senanayake et al., 1997). ORF I was identified 
from N gene in coronavirus MHV and PEDV too (Fischer et al., 1997; Singh 
1999). This bicistronic N enables coronaviruses to fully manipulate the genome.  
In the in vitro translation product from pKTO-N, the amount of N and the 
amount of 9b are at similar levels. It is known that N is a major structural protein, 
and its expression level is significantly high in virus-infected cells. This 
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observation suggests that the expression level of 9b is rather high too. The high 
expression level of protein 9b is supported by other reports as well. Anti-9b 
antibodies were detected in the sera of different SARS patients from weeks 2 to 30 
after the onset of SARS in their systems, while antibodies against most of the other 
accessory proteins are not detected (Qiu et al., 2005). In another report, the titer of 
antibodies against 9b epitopes are as high, or even higher, than the titer of 
antibodies against structural protein epitopes in some SARS patients (Chow et al., 
2006).  
Because these tests are based on antibody-antigen interaction, the signal 
strength may be affected by sensitivity and specificity of different types of 
antibodies, or by other factors like the incubation time or exposure time. The 
detection of the in vitro translation results is based on signals from radioactive [
35
S] 
methionine in the protein, so the signals allow for the direct comparison of two 
different proteins. Our results provide direct evidence that the expression level of 
9b is as high as that of N under the same conditions. This high level expression is 
in constrast to the low expression level of the I protein in bovine coronavirus, in 
which only a small percentage of ribosomes passed over the first initiation site for 
N and use the second site (Senanayake and Brian, 1997). 
The high expression level of 9b may be due to two reasons. One reason is 
that the two translation initiation sites are close. The translation initiation site for 
9b is 7 nucleotides downstream of the translational initiation site of  N protein. A 
study on Turnip yellow mosaic virus (TYMV) RNAs (Matsuda and Dreher, 2006) 
showed that close spacing between AUGs contributed to the bicistronic character 
on a eukaryotic mRNA, and the increase in space resulted in a decrease in 
downstream initiation and increase in upstream initiation.  
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Due to the length limitation of their genome, RNA viurses normally 
maximize the usage of their gene information. Coronaviruses have bicistronic 
mRNA, and even tricistronic mRNA to make full use the genome (Liu and Inglis, 
1992). The bicistronic mRNA may be translated using different mechanisms, like 
ribosomal leaky scanning, internal initiation with an internal ribosomal entry site. 
The high expression level of protein 9b also suggests its importance in the life 
history of SARS-CoV. 
3.3.2 SARS-CoV 9b mediates virion assembly 
While the functions of I proteins from other coronaviruses are still unclear, 
we show here that 9b mediates virion assembly and release, and this mediation may 
be carried out via its interaction with E and M. The assembly process of 
coronaviruses is not yet fully understood. In other coronaviruses, E and M are 
necessary and sufficient for virion formation and release (Baudoux et al., 1998; 
Bos et al., 1996). However, in the case of SARS-CoV, the combination of E and 
M, and the combination of E and N were all reported to lead to successful VLP 
release (Huang et al., 2004).  
Here we demonstrated that co-expression of 9b and M is sufficient for VLP 
formation as well. The function of 9b in facilitating virion assembly could also 
explain why N and M can lead to efficient VLP formation in SARS CoV, since 9b 
is hidden in the encoding region of N. In fact, it may be protein 9b that carries out 
the function during virus assembly when N and M are co-expressed. As shown in 
Figure 3.3, co-expression of M and N∆9b failed to form VLPs. Furthermore, 
during SARS-CoV virion egress, E and 9b may have synergistic effects. Siu et al. 
have reported that the co-expression of M, E and N lead to much higher release of 
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SARS-CoV VLPs, while the efficiency is much lower when either M and E, or M 
and N are co-expressed in Vero cells (Siu et al., 2008). However, it is also noticed 
that SARS-CoV can be recovered without both E and 9b (Marta et al., 2008), and 
this mutant virus strain can replicate just as efficiently in Vero cells. According to 
this report, there may be other proteins that could compensate the functions of both 
9b and E. This implies that the assembly process for SARS-CoV is extremely 
complicated. As such, further studies are still necessary to explore this field. 
ORF9b may facilitate virion assembly via interactions with structural 
proteins M and E. The process of virion assembly in coronaviruses is partially 
illustrated. M is the most abundant envelope protein that drives coronavirus 
assembly in the ERGIC (Corse et al., 2003; Stertz et al., 2007). Other membrane 
proteins E and S are integrated into the structure via interaction with M (McBride 
et al., 2007). N and viral RNA were also integrated into the virions via interaction 
with c-terminal domain of M (Narayanan et al., 2001). Here, our 
immunoprecipitation results showed that 9b is able to interact with M and E, both 
of which play key roles during virion assembly. 9b is localized in the ERGIC, as 
well as in other membrane structures (McBride et al., 2007). According to these 
facts, 9b may possibly facilitate the assembly via transport the virion structural 
protein and viral RNA into the assembly site.  
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CHAPTER 4. FUNCTIONAL CHARACTERIZATION  
OF SARS-COV ORF6 
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4.1 Introduction 
As discussed in Chapter 1, SARS-CoV ORF6 accelerates murine 
coronavirus infections and enhances the virulence of MHV (Pewe, 2005; Tangudu, 
2007). However, SARS-CoV with deleted ORF6 (rSARS-CoVΔ6) can still infect 
mice, although the replication efficiency of rSARS-CoVΔ6 is not as high as that in 
SARS-CoV (Zhao et al., 2009). ORF6 was reported to interfere with both the 
interferon pathway and the apoptosis pathway (Kopecky-Bromberg et al., 2007; Ye 
et al., 2008). These reports suggest that ORF6 plays more important roles in virus-
host interaction instead of in the virus replication cycle. To study functions of 
ORF6 in virus-host interactions, we used microarray to study the transcription 
profiles in H1299 cells stably expressing ORF6.  
4.2 The engineering of H1299 and rIBV with stable expression of SARS-CoV 
ORF6 
4.2.1 Establishment of H1299 cells with stable expression of SARS-CoV ORF6 
To investigate the functions of ORF6 in host cells, H1299 cell lines stably 
expressing SARS-CoV ORF6 (S6) were engineered. Sequences of SARS-CoV 
ORF6 were first inserted into a pXj40 vector, which contains a HMCV promoter 
for transcription in cells. The pXJ40 vector also contains a neomycin resistant gene 
to enable the selection with G418 in cells. The plasmid pXJ40-S6 was first 
transfected into H1299 cells with Effectene (Qiagen). Cells were trypsinized and 
passaged to a new plate. The cells were cultured in medium with G418 at a 
concentration of 400 µg/ml for selection. Colonies appeared in approximately 2 
weeks’ time. Colonies were picked with sterile cotton buds and maintained with 
200 µg/ml of G418 every 2 passages. The expression level of ORF6 in H1299-WT 
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and H1299-S6 were examined via Western blotting, as shown in Figure 4.1. Stable 
expression of significant amount of ORF6 was detected in the selected cell strains. 
4.2.2 The replication efficiency of IBV is higher in H1299-S6 cells than in 
H1299-WT cells 
H1299-WT cells and H1299-S6 cells were infected with IBV at a MOI of 1. 
The replication efficiency was examined under a microscope at 8, 16, 20, 24 and 
28 hours post infection. As shown in Figure 4.2, IBV replicates faster in H1299-S6 
cells than in H1299-WT cells. More CPE appeared in H1299-S6 cells at 16 hours 
post infection. At 28 hours post infection, 100% CPE was observed in H1299-S6 
cells and most of these cells were floating, whereas for H1299-WT cells, single, 
uninfected cells could still be observed and the CPE was still increasing. These 
observations showed that the IBV replication efficiency is different in these two 
cell types. This difference hindered the detection of apoptosis caused by IBV in 
H1299-WT cells and H1299-S6 cells. When the two cell lines were infected by 
IBV, they may have different apoptotic responses, but it is not clear if this 
difference is caused by altered virus replication efficiency or by the cell itself. 
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Figure 4.1 Dimerization of IRF3 in H1299-WT and H1299-S6 cells  
H1299 cells with stable expression of SARS-CoV ORF6 were established. H1299 
were transfected with plasmids pXJ40-S6 using Effectene (Qiagen) according to 
manufacturer’s guideline. G418 400µg/ml was added into culture medium 24 hours 
post infection for selection. The medium with G418 was changed every 24 hours to 
select the drug resistant colonies. Colonies were picked with sterile cotton buds and 
maintained with 200 µg/ml of G418 every 2 passages. The expression level of 
ORF6 in H1299 and H1299-S6, respectively were examined Western blotting. 
H1299 and H1299-S6 were first treated with poly:(IC). After poly:(IC) treatment, 
cells were lysed in with a native lysis buffer, and IRF3 is detected with native gel 
electrophoresis. Gels were electroblotted to polyvinylidene difluoride (PVDF) 
membrane, and detected with specific antibodies. Antibodies against IRF3, SARS-
CoV ORF6, and tubulin were used in columns as indicated.  
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Figure 4.2 Replication efficiency of IBV in H1299-WT and H1299-S6 cells 
H1299-WT cells and H1299-S6 cells were infected with IBV at MOI 1 in 
triplicates, and representative pictures are shown here. The cells were incubated 
with IBV for 1 h, and then fresh medium with FBS was changed to maintain cell 
growth. Cells were observed under microscope at 0, 8, 16, 20, 24 and 28 hours post 
IBV infection. CPE was observed as an indication of virus replication efficiency. 
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4.2.3 Engineering of rIBV with stable expression of SARS-CoV ORF6 
To eliminate any difference caused by virus replication, two IBV virus 
strains were engineered using a reverse-genetic approach. As illustrated in figure 
2.1 on page 63, IBV-luciferase (IBV-Luc) and IBV-S6 were produced. In general, 
the IBV genome was divided into 5 fragments. Fragment A contains IBV sequence 
nucleotides from 1 to 5751, and a T7 promoter region was inserted ahead of the 5’-
end. Fragment B contains IBV sequence nucleotides form 5752 to 8693. Fragment 
C contains IBV sequence nucleotides from 8694 to 15520. Fragment D contains 
IBV sequence nucleotides from 15521 to 20900. Restriction sites for either BsmBI 
or BsaI were introduced into both the 5’ and 3’ ends of the fragments Fragment E 
contains IBV sequence nucleotides from 20901 to 27608, and 30 As were inserted 
at the 3’-end.  
These 5 fragments were then cloned into pGEM vectors or pCR-XL-TOPO 
to facilitate modification. Sequences of SARS-CoV ORF6 were PCR amplified 
with specific primers, and were inserted between nucleotides 25180 and 25181 in 
fragment E. After the modification of each fragment, respectively, the plasmids 
were digested such that the 5 fragments were re-obtained. These fragments were 
then ligated to form a full-length IBV genome with a T7 promoter at the 5’-end. 
This full-length cDNA was in vitro transcribed into virus genomic RNA, which 
was then electroporated into Vero cells for virus recovery. The virus was 
subsequently amplified in Vero cells for virus stock preparation. This virus was 
named IBV-S6, because it has SARS-CoV ORF6 gene in its genome. IBV-Luc was 
generated using the same method, with a luciferase gene inserted at the same 
position of IBV instead. 
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4.2.4 Characterization of IBV-S6 and IBV-Luc 
 Expression of ORF6 was confirmed with western blotting. H1299 cells 
were infected with IBV-S6 or IBV-Luc at a MOI of 1 at 24 hours post transfection. 
The cells were incubated with IBV for 1 h, and then fresh medium with FBS was 
changed to maintain cell growth. Cells were harvested 0, 8, 16 and 24 hours post 
infection. Cell lysate was separated with SDS-PAGE. Gels were electroblotted to 
polyvinylidene difluoride (PVDF) membrane, and detected with antibodies against 
SARS-CoV ORF6 and SARS-CoV N. As shown later in Figure 4.7, expression of 
ORF6 was detected in cells infected by IBV-S6 at 8, 16 and 24 hours post 
infection. SARS-CoV N was also detected in cells infected with both IBV-Luc and 
IBV-S6. 
 Growth curves of IBV-Luc and IBV-S6 were then measured. Confluent 
monolayers of Vero cells on 6-well plates were infected with IBV-S6 or IBV-Luc, 
and harvested at 0, 4, 8, 12, 16, 20, 24, 28 and 32 hours post-infection. Viral stocks 
were prepared by repeated freeze/thaw cycles of the cells thrice. The titration of 
each sample was determined by infecting confluent Vero cells on 6-well plates 
with 10-fold serial dilutions of each viral stock. As shown in Figure 4.3, both 
viruses showed similar growth kinetics in Vero cells, reaching peak titres at 16 
hours post-infection. 
Stable expression of SARS-CoV ORF6 and luciferase were detected from 
recombinant IBV after passages in Vero cells. IBV-Luc stably expressed luciferase 
activity for at least 15 passages. IBV-S6 has stable expression of SARS-CoV 
ORF6 for at least 5 passages. IBV-S6 was not further passaged, so no data was 
available to show the expression level of SARS-CoV ORF6 in more passages. 
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Figure 4.3 Growth curves of IBV-Luc and IBV-S6 
Vero cells were infected with IBV-Luc or IBV-S6 at MOI of 0.1, and frozen down 
at various time points within a 0-32 hour interval post-infection for virus titration 
through plaque assay after three rounds of freeze-thaw cycles. Confluent 
monolayers of Vero cells on six-well plates were infected with 100µl of 10-fold 
serially diluted virus stock. After 1 h of incubation at 37ºC, cells were washed 
twice with PBS and cultured in 3 ml of DMEM containing 0.5% carboxymethyl 
cellulose for 3 days. The cells were fixed and stained with 0.1% toluidine blue. The 
number of plaques was counted and the virus titre was calculated as pfu/ml. 
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4.3 SARS-CoV ORF6 alters the transcription profile of genes from the 
interferon pathway, cell death pathway and other pathways 
4.3.1 Microarray analysis of host gene profiles in H1299-S6 and H1299-WT 
The expression level of host genes in H1299-S6 and H1299-WT were then 
compared using a microarray analysis. Total RNA from H1299-WT and H1299-S6 
cells were then subjected to microarray analyses. RNA was extracted with Trizol 
(Invitrogen) according to the protocol provided. The mRNAs were then measured 
with GeneChip
®
 Human Genome U133 Plus 2.0 Array. Groups of genes were 
expressed at different levels in these two cell lines. Genes with over 2 fold change 
were analyzed with Ingenuity Pathway Analysis (IPA). As shown in Table 4.1, 
genes in functional groups such as cell death, dell differentiation, cell morphology, 
inflammatory response, have been significantly changed. To further identify 
exactly which are the signaling pathways ORF may interfere with, genes with over 
2 fold change were further analyzed with Partek Genomics Suite. As shown in 
Table 4.2, genes in the NF-kB signaling pathway and genes in the Signal 
transducers and activators of transcription (STAT) pathway were identified. 
Genes in different functional groups were shown to be significantly 
changed in presence of SARS-CoV ORF6. These functional groups include cell 
death, cancer, lipid metabolism, cell cycle, cellular assembly and organization, 
molecular transport, inflammatory response and antigen presentation, among 
others. Among these groups of genes, we are especially interested in genes from 
the interferon and cell death pathways, respectively, as these two pathways play 
key roles during virus infection. The interference of ORF6 with these two 
pathways was further studied to confirm the microarray results.  
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4.3.2 Comparison of microarray data from H1299-S6 with microarray data 
from cells and from patients that were infected by SARS-CoV 
 Microarray analysis on cells or patients that were infected by SARS-CoV 
has been reported earlier. Expression files of immune response genes of peripheral 
blood mononuclear cells (PBMCs) derived from SARS patients were analyzed 
against gene files from PBMCs derived healthy people (Reghunathan et al., 2005). 
The genes changed in H1299-S6 cells and genes changed in PBMCs from SARS 
patients were compared using Partek Genomics Suite, and 9 genes were identified 
as significantly changed in both cells (Table 4.3). Another group of researchers 
used SARS-CoV and human coronavirus 229E to infect Huh7 cells, and did 
microarray analysis (Tang et al., 2005). The changed genes in in H1299-S6 cells 
and genes changed in Huh7 infected by SARS-CoV were compared using Partek 
Genomics Suite as well, and 6 genes were identified to change in both instances.  
 Among these genes, NF-kB is changed in all three experiments. NF-kB is 
an important transcription factor playing key roles in interferon pathway. Other 
genes include those functioning in the apoptosis pathway such as BIRC3, and 
genes functioning in the cell cycle include CDKN2C and KLF4. 
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Table 4.1 Genes in different functional groups affected by SARS-CoV ORF6 
Category  p-value* Molecules 
Cell Death 2.37E-08-
1.01E-02 
SLC7A11, IL32, PDE4D, BIRC5, VEGFA, IFIH1, ADA, 
NUPR1, BCL2L2, ITGB4, KLF2, SOX4, MED1, HSPA9, 
RRM2, KLF4, TUB, ITCH, ITGAM, CCND2, SUMO1, 
BHLHE40, APOE, SCD, HIST1H1C, IFI27, DDIT3, 
CDC42, GDF15, CLU, NUMB, SLC2A3, TCF12, GPC1, 
CD55, NEK2, KL, TM2D1, FASN, SLC11A2, PTPRZ1, 
IFI6, STAT1, PLSCR1, TACC3, TRIB3, CEBPB, DLC1, 






APOE, GBP1, IFI27, GDF15, CLU, BIRC5, VEGFA, 
IFIT1, IFI44L, KL, FASN, ADA, IFI30, IFITM1, IFI6, 
ITGB4, STAT1, PLSCR1, IFIT3, CEBPB, LAMC2, 






DLGAP5, SLC7A11, INSIG1, LPPR4, PDE4D, TBC1D2, 
BIRC5, VEGFA, IFIH1, SMS, IFI44L, IFI30, ADA, 
NUPR1, CDKN3, BCL2L2, IMPA2, RGS14, ITGB4, 
FAM172A, KLF2, SOX4, IFIT3, CKS2, MED1, RRM2, 
CRELD1, TUB, ITCH, COL4A5, SSBP1, ITGAM, 
CCND2, MATN2, BHLHE40, GTSE1, SAMD4A, APOE, 
SCD, ZFYVE26, CDC42, DDIT3, IFI27, GBP1, GDF15, 
NUMB, CLU, GPHN, SLC2A3, TCF12, GPC1, IFIT1, 
CD55, NEK2, KL, TM2D1, CALD1, FASN, SLC11A2, 
ACAD8, PTPRZ1, IFITM1, IFI6, STAT1, PLSCR1, 
CEBPB, DLC1, LAMC2, SERPINE2, ISG15, IFI44, 




DLGAP5, SLC7A11, INSIG1, IL32, PDE4D, BIRC5, 
VEGFA, IFIH1, SMS, IFI44L, ADA, IFI30, NUPR1, 
CDKN3, BCL2L2, ITGB4, SOX4, IFIT3, CKS2, RRM2, 
CRELD1, KLF4, CCND2, SUMO1, BHLHE40, IFIT2, 
TMPO, SCD, APOE, ZFYVE26, CDC42, DDIT3, GBP1, 
IFI27, GDF15, CLU, SLC2A3, IFIT1, GPC1, CD55, 
NEK2, KL, CALD1, FASN, IFITM1, STAT1, MYH1, 
CEBPB, DLC1, LAMC2, SERPINE2, IFI44, ISG15, 
DLEU2, SLC16A1, TGFA, DGAT1, PLAU, EHHADH, 
QPCT 





SCD, APOE, CDC42, INSIG1, IL32, CLU, TRIB3, 
CEBPB, IFRD1, VEGFA, GPC1, KL, FASN, TGFA, 





APOE, SCD, CDC42, INSIG1, IL32, GLS, CLU, RRM2, 
TRIB3, CEBPB, VEGFA, IFRD1, GPC1, SMS, KL, 




APOE, DLGAP5, CDC42, DDIT3, GDF15, NUMB, CLU, 
BIRC5, VEGFA, GPC1, NEK2, TMEM8B, FASN, 
CDKN3, RGS14, ITGB4, STAT1, KLF2, TACC3, CKS2, 
KIF4A, RPRM, CEBPB, KLF4, CCND2, BHLHE40, 






IFIT3, APOE, SCD, SLC7A11, IFI27, MED1, IL32, CLU, 
CEBPB, PDE4D, VEGFA, IFIT1, KL, TGFA, ADA, 






APOE, SCD, INSIG1, IL32, CLU, PDE4D, BIRC5, 






APOE, CDC42, DDIT3, GDF15, NUMB, TRIB3, CEBPB, 
KLF4, SERPINE2, VEGFA, NEK2, FASN, NUPR1, 






APOE, TACC3, CDC42, DDIT3, CLU, TRIB3, DLC1, 





DLGAP5, APOE, ZFYVE26, IFI27, GDF15, CLU, 
RRM2, ISG15, BIRC5, VEGFA, SMS, GPC1, CD55, 
ITGAM, IFI44L, BHLHE40, FASN, NUPR1, IFI30, ADA, 






DLGAP5, SLC7A11, INSIG1, IL32, PDE4D, BIRC5, 
VEGFA, IFIH1, ADA, NUPR1, IFI30, CDKN3, BCL2L2, 
ITGB4, KLF2, SOX4, IFIT3, CKS2, MED1, RRM2, 
KLF4, ITCH, CCND2, ITGAM, SUMO1, BHLHE40, 
APOE, ZFYVE26, GBP1, DDIT3, CDC42, GDF15, 
NUMB, CLU, TCF12, GPC1, CD55, NEK2, FASN, 
IFITM1, STAT1, PLSCR1, TACC3, CEBPB, DLC1, 





DLGAP5, SCD, APOE, SLC7A11, INSIG1, GDF15, 
CLU, PDE4D, SLC2A3, BIRC5, VEGFA, NEK2, FASN, 
CALD1, CDKN3, IFITM1, ITGB4, STAT1, MED1, 
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RRM2, CRELD1, CEBPB, KLF4, SERPINE2, CCND2, 





APOE, ZFYVE26, DDIT3, GDF15, NUMB, PDE4D, 
TCF12, BIRC5, VEGFA, KL, ADA, BCL2L2, STAT1, 
KLF2, PLSCR1, MED1, CEBPB, KLF4, SERPINE2, 







DLGAP5, APOE, TACC3, CDC42, KIF4A, NUMB, CLU, 
DLC1, LAMC2, TUB, BIRC5, SERPINE2, VEGFA, 





IFRD1, SCD, APOE, DDIT3, INSIG1, KL, FASN, CLU, 











IFI27, LPPR4, ISG15, VEGFA, IFIH1, IFIT1, CD55, 





APOE, CDC42, IL32, GDF15, CLU, PDE4D, TCF12, 
VEGFA, IFIH1, IFIT1, CD55, IFI44L, KL, ADA, NUPR1, 
IFI6, STAT1, KLF2, PLSCR1, CEBPB, TUB, KLF4, 
ISG15, IFI44, ITCH, ITGAM, PLAU, IFIT2 
Hematopoiesis 1.57E-04-
1.01E-02 
SOX4, APOE, HIST1H1C, TACC3, CDC42, MED1, 
CEBPB, KLF4, TCF12, BIRC5, VEGFA, SLC11A2, 





APOE, SCD, INSIG1, MED1, CLU, RRM2, CEBPB, 
DLC1, PDE4D, ISG15, VEGFA, FASN, TGFA, CDKN3, 





HIST1H1C, APOE, SCD, SLC7A11, CDC42, DDIT3, 
INSIG1, IL32, GDF15, CLU, NUMB, PDE4D, BIRC5, 
TCF12, IFIH1, VEGFA, GPC1, FASN, SLC11A2, ADA, 
PTPRZ1, ITGB4, STAT1, KLF2, PLSCR1, SOX4, 
TACC3, MED1, RRM2, TRIB3, CEBPB, DLC1, KLF4, 






HIST1H1C, APOE, CDC42, GDF15, NUMB, CLU, 
PDE4D, SLC2A3, VEGFA, IFIH1, IFIT1, CD55, CALD1, 
ADA, IFI30, PTPRZ1, IFITM1, IMPA2, STAT1, 
FAM172A, KLF2, SOX4, RRM2, HBE1, CEBPB, ISG15, 





APOE, HIST1H1C, MED1, RRM2, CLU, HBE1, PDE4D, 
SLC2A3, BIRC5, VEGFA, ITGAM, KL, FASN, ADA, 
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HIST1H1C, APOE, CDC42, DDIT3, GDF15, CLU, 
PDE4D, BIRC5, TCF12, VEGFA, KL, SLC11A2, ADA, 
STAT1, KLF2, PLSCR1, SOX4, TACC3, MED1, CEBPB, 






VEGFA, APOE, GDF15, CLU, RRM2, TGFA, ITGB4, 






APOE, CDC42, IL32, ITGA10, CEBPB, DLC1, LAMC2, 





APOE, CDC42, MED1, CLU, CEBPB, LAMC2, BIRC5, 
IFRD1, VEGFA, CD55, ITGAM, CCND2, KL, 





VEGFA, APOE, IFIT1, CD55, DLEU2, IFI27, RRM2, 





SCD, APOE, SLC7A11, DDIT3, IFI27, IL32, CLU, 
NUMB, PDE4D, FAM55C, TCF12, BIRC5, IFIH1, 
VEGFA, IFIT1, CD55, KL, CALD1, FASN, TM2D1, 
ADA, IFI30, PTPRZ1, IFITM1, IMPA2, IFI6, STAT1, 
KLF2, PLSCR1, MED1, RRM2, CEBPB, DLC1, LAMC2, 
ISG15, SERPINE2, COL4A5, ITGAM, MATN2, 







SCD, DDIT3, CDC42, MED1, INSIG1, TRIB3, CEBPB, 





CDC42, GBP1, GDF15, CLU, NUMB, RRM2, DLC1, 









APOE, CDC42, CLU, CEBPB, KLF4, BIRC5, VEGFA, 
IFRD1, CCND2, KL, CALD1, BHLHE40, PLAU, ITGB4, 
STAT1, KLF2 
*P-value stands for the possibility value. The lower the value is, the higher 
possibility that the analysis is reliable.  
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Gene abbreviations are as follows: 
ACAD8, acyl-CoA dehydrogenase family, member 8; ADA, adenosine deaminase; 
APOE, apolipoprotein E; BCL2L2, BCL2-like 2; BHLHE40, basic helix-loop-helix 
family, member e40; BIRC5, baculoviral IAP repeat containing 5; CALD1, 
caldesmon 1; CCND2, cyclin D2; CD55, CD55 molecule; CDC42, cell division 
cycle 42; CDKN3, cyclin-dependent kinase inhibitor 3; CEBPB, CCAAT/enhancer 
binding protein (C/EBP), beta; CKS2, CDC28 protein kinase regulatory subunit 2; 
CLU, clusterin; COL4A5,collagen, type IV, alpha 5; CRELD1, cysteine-rich with 
EGF-like domains 1; CTH, cystathionase; DAZ2, deleted in azoospermia 2; 
DDIT3, DNA-damage-inducible transcript 3; DGAT1, diacylglycerol O-
acyltransferase 1; DLC1, deleted in liver cancer 1; DLC1, dynein, light chain, 
LC8-type 1; DLEU2, deleted in lymphocytic leukemia 2; DLGAP5, discs, large 
(Drosophila) homolog-associated protein 5; EHHADH, enoyl-CoA, hydratase/3-
hydroxyacyl CoA dehydrogenase; FAM172A, family with sequence similarity 172, 
member A; FAM55C, family with sequence similarity 55, member C; FASN, fatty 
acid synthase; GBP1, guanylate binding protein 1, interferon-inducible; GDF15, 
growth differentiation factor 15; GLS, glutaminase; GPC1, glypican 1; GPHN, 
gephyrin; GTSE1, G-2 and S-phase expressed 1; HBE1, hemoglobin, epsilon 1; 
HIST1H1C, histone cluster 1, H1c; HSPA9, heat shock 70kDa protein 9 (mortalin) 
; IFI27, interferon, alpha-inducible protein 27; IFI30, interferon, gamma-inducible 
protein 30; IFI44, interferon-induced protein 44; IFI44L, interferon-induced 
protein 44-like; IFI6, interferon, alpha-inducible protein 6; IFIH1, interferon 
induced with helicase C domain 1; IFIT1, interferon-induced protein with 
tetratricopeptide repeats 1; IFIT2, interferon-induced protein with 
tetratricopeptide repeats 2; IFIT3, interferon-induced protein with 
tetratricopeptide repeats 3; IFITM1, interferon induced transmembrane protein 1; 
IFRD1, interferon-related developmental regulator 1; IL32, interleukin 32; 
IMPA2, inositol(myo)-1(or 4)-monophosphatase 2; INSIG1, insulin induced gene 
1; ISG15, ISG15 ubiquitin-like modifier; ITCH, itchy E3 ubiquitin protein ligase 
homolog; ITGA10, integrin, alpha 10; ITGAM, integrin, alpha M; ITGB4, 
integrin, beta 4; KIF4A, kinesin family member 4A; KL, klotho; KLF2, Kruppel-
like factor 2; KLF4, Kruppel-like factor 4; KYNU, kynureninase; LAMC2, 
laminin, gamma 2; MATN2, matrilin 2; MED1, mediator complex subunit 1; 
MED1, methyl-CpG binding domain protein 4; MYH1, myosin, heavy chain 1; 
NEK2, NIMA (never in mitosis gene a)-related kinase 2; NUMB, numb homolog; 
NUPR1, nuclear protein, transcriptional regulator, 1; PDE4D, phosphodiesterase 
4D, cAMP-specific; PLAU, plasminogen activator, urokinase; PLSCR1, 
phospholipid scramblase 1; PTPRZ1, protein tyrosine phosphatase, receptor-type, 
Z polypeptide 1; QPCT, glutaminyl-peptide cyclotransferase; RGS14, regulator of 
G-protein signaling 14; RPRM, reprimo, TP53 dependent G2 arrest mediator 
candidate; RRM2, ribonucleotide reductase M2; SAMD4A, sterile alpha motif 
domain containing 4A; SCD, stearoyl-CoA desaturase (delta-9-desaturase); SCD, 
solute carrier family 22 (organic cation/carnitine transporter), member 5; 
SEPHS1, selenophosphate synthetase 1; SERPINE2, serpin peptidase inhibitor, 
clade E (nexin, plasminogen activator inhibitor type 1), member 2; SLC11A2, 
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 
2; SLC16A1, solute carrier family 16, member 1; SLC2A3, solute carrier family 2 
(facilitated glucose transporter), member 3; SLC7A11, solute carrier family 7 
(anionic amino acid transporter light chain, xc- system), member 11; SMS, 
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spermine synthase; SMS, retinoic acid induced 1; SOX4, SRY (sex determining 
region Y)-box 4; SSBP1, single-stranded DNA binding protein 1; STAT1, signal 
transducer and activator of transcription 1; SMT3, suppressor of mif two 3 
homolog 1; TACC3, transforming, acidic coiled-coil containing protein 3; 
TBC1D2, TBC1 domain family, member 2; TCF12, transcription factor 12; TGFA, 
transforming growth factor, alpha; TM2D1, TM2 domain containing 1; TMEM8B, 
transmembrane protein 8B; TMPO, thymopoietin; TRIB3, tribbles homolog 3; 
TUB, tubby homolog; VEGFA, vascular endothelial growth factor A; ZFYVE26, 
zinc finger, FYVE domain containing 26. 
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Table 4.2 Signaling pathways with gene expression level changed in H1299-
S6 
 
Name p-value* Molecules 
FibronectinR -> NF-kB signaling 0.000182322 ITGAM, NFKBIA, ITGAV, 
NFKB2, IKBKG, PIK3R3, 
ITGA10 
MacrophageR -> CEBPB/NFkB 
signaling 
0.00023861 ITGAM, NFKBIA, CEBPB, 
NFKB2, IKBKG, PIK3R3 
UrokinaseR -> STAT signaling 0.000292809 PLAU, PLAUR, STAT1 
ALK -> STAT signaling 0.00614249 STAT1, MDK 
IL7R -> FOXO/NF-kB signaling 0.00637201 NFKBIA, NFKB2, IKBKG, 
PIK3R3 
FibronectinR -> CTNNB signaling 0.00773327 ITGAM, ITGAV, PIK3R3, 
ITGA10 
FibronectinR -> ICAP-1A/MYC 
signaling 
0.00898512 ITGAM, ITGAV, ITGA10 
DDR1 -> NF-kB signaling 0.0102473 NFKBIA, NFKB2, IKBKG 
NGFR -> NF-kB signaling 0.0130663 NFKBIA, NFKB2, IKBKG 
IL13R -> STAT signaling 0.0141488 STAT1, IL13RA1 
ErythropoietinR -> NF-kB 
signaling 
0.0173808 NFKBIA, NFKB2, IKBKG, 
PIK3R3 
TLR4/5/7/9 -> NF-kB signaling 0.0180468 NFKBIA, NFKB2, IKBKG 
Apoptosis 0.0629697 BIRC3, BCL2L2, BIRC5, 
NFKB2 
EGFR/ERBB -> STAT signaling 0.0643487 TGFA, STAT1 
FibronectinR -> AP-1/ELK-SRF 
/SREBF signaling 
0.0682646 ITGAM, ITGAV, PIK3R3, 
ITGA10 
Heme oxidation 0.0786645 HBE1, KL, BLVRB 
Cell Cycle Regulation 0.0872867 SGSM3, H2AFJ, TGFA, 
PLAUR, VEGFA, NFKBIA, 
CDC42, CTGF, MKI67, 
GADD45A, CDKN2C, CCNA2, 
FEN1, HDAC7, NFKB2, 
RHOB, IKBKG, CCND2, 
CCNB1, SPAG5, CENPE, 
AURKB, TPX2, EIF1AX, 
BUB1B, KIF23, NUMB, 
PIK3R3, WARS, FZD1, NQO1, 
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PTPRZ1, NEK2, SF3B3, 
MED1, CDC27, PARVA, 
RGS14, Tra2a, TACC3, 
CDC16, KIF4A, POM121, 
HIST1H1C, GTSE1, RBM4, 
SSBP1, DLGAP5, DDX21, 
MED24, STAG2, EIF2B2, 
NARF 
VEGFR -> CTNNB signaling 0.108296 VEGFA, PIK3R3 
UrokinaseR -> ELK-SRF signaling 0.120248 PLAU, PLAUR, PIK3R3 
Biosynthesis of cholesterol 0.125745 FDFT1, FDPS, DHCR7 
GFR -> FOXO3A signaling 0.132825 TGFA, VEGFA, CTGF, 
PIK3R3 
GFR -> NCOR2 signaling 0.135114 TGFA, VEGFA, CDC42, 
CTGF, PIK3R3 
*P-value stands for the possibility value. The lower the value is, the higher 
possibility that the analysis is reliable.  
 
Gene abbreviations are as follows: 
 
AURKB, aurora kinase B; BCL2L2, BCL2-like 2; BIRC3, baculoviral IAP repeat containing 3; 
BIRC5, baculoviral IAP repeat containing 5; BLVRB, biliverdin reductase B; BUB1B, budding 
uninhibited by benzimidazoles 1 homolog beta; CCNA2, cyclin A2; CCNB1, cyclin B1; CCND2, 
cyclin D2; CDC16, cell division cycle 16 homolog; CDC27, cell division cycle 27 homolog; CDC42, 
cell division cycle 42; CDKN2C, cyclin-dependent kinase inhibitor 2C; CEBPB, CCAAT/enhancer 
binding protein (C/EBP), beta; CENPE, centromere protein E; CTGF, connective tissue growth 
factor; DDX21, DEAD (Asp-Glu-Ala-Asp) box polypeptide 21; DHCR7, 7-dehydrocholesterol 
reductase; DLGAP5, discs, large (Drosophila) homolog-associated protein 5; EIF1AX, eukaryotic 
translation initiation factor 1A; EIF2B2, eukaryotic translation initiation factor 2B, subunit 2 beta; 
FDFT1, farnesyl-diphosphate farnesyltransferase 1; FDPS, farnesyl diphosphate synthase; FEN1, 
flap structure-specific endonuclease 1; FZD1, frizzled family receptor 1; GADD45A, growth arrest 
and DNA-damage-inducible, alpha; GTSE1, G-2 and S-phase expressed 1; H2AFJ, H2A histone 
family, member J; HBE1, hemoglobin, epsilon 1; HDAC7, histone deacetylase 7; HIST1H1C, 
histone cluster 1; IKBKG, inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase 
gamma; IL13RA1, interleukin 13 receptor, alpha 1; ITGA10, integrin, alpha 10; ITGAM, integrin, 
alpha M; ITGAV, integrin, alpha V; ITGB4, integrin, beta 4; ITGB5, integrin, beta 5; KIF23, 
kinesin family member 23; KL, klotho; MDK, midkine (neurite growth-promoting factor 2); MED1, 
mediator complex subunit 1; MBD4, methyl-CpG binding domain protein 4; MED24, mediator 
complex subunit 24; MED22, mediator complex subunit 22; MKI67, antigen identified by 
monoclonal antibody Ki-67; NARF, nuclear prelamin A recognition factor; NEK2, NIMA (never in 
mitosis gene a)-related kinase 2; NFKB2, nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2; NFKBIA, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha; NQO1, NAD(P)H dehydrogenase, quinone 1; NUMB, numb homolog; PARVA, parvin, 
alpha; PIK3R3, phosphoinositide-3-kinase, regulatory subunit 3 (gamma); PLAU, plasminogen 
activator, urokinase; PLAUR, plasminogen activator, urokinase receptor; POM121, POM121 
membrane glycoprotein; RBM4, RNA binding motif protein 4; RGS14, regulator of G-protein 
signaling 14; RHOB, ras homolog gene family, member B; SF3B3, splicing factor 3b, subunit 3; 
SGSM3, small G protein signaling modulator 3; SOX4, SRY (sex determining region Y)-box 4; 
SPAG5, sperm associated antigen 5; SSBP1, single-stranded DNA binding protein 1; STAG2, 
stromal antigen 2; STAT1, signal transducer and activator of transcription 1; TACC3, 
transforming, acidic coiled-coil containing protein 3; TGFA, transforming growth factor, alpha; 
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TRA2A, transformer 2 alpha homolog; VEGFA, vascular endothelial growth factor A; WARS, 
tryptophanyl-tRNA synthetase. 
  129 
Table 4.3 Common genes changed in the two different sets of microarray data 
 
H1299-S6 vs. PBMC-SARS 
microarray 












Gene abbreviations are as follows: 
BIRC3, baculoviral IAP repeat containing 3; CDKN2C, cyclin-dependent kinase 
inhibitor 2C; CENPE, centromere protein E; CLU, clusterin; HBE1, hemoglobin, 
epsilon 1; HIST1H1C, histone cluster 1, H1c; IMPA2, inositol(myo)-1(or 4)-
monophosphatase 2; ITGAM, integrin, alpha M; KLF4, Kruppel-like factor 4; 
NFIL3, nuclear factor, interleukin 3 regulated; NFKBIA, nuclear factor of kappa 
light polypeptide gene enhancer in B-cells inhibitor, alpha; RHOBTB3, Rho-
related BTB domain containing 3; RRM2, ribonucleotide reductase M2; SLC2A3, 
solute carrier family 2 member 3. 
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4.4 SARS-CoV ORF6 inhibits interferon production 
4.4.1 Introduction  
The activation of the interferon pathway is an important host response against 
viral infection. When the host immune system is exposed to viral pathogens, it 
reacts straightaway by triggering a diverse array of defence mechanisms in order to 
establish a more efficacious shield. The first line of defence is the mounting of an 
innate immune response, as characterized by the increased production of type I 
interferons (IFN-α and IFN–β) and other inflammatory cytokines. These, in turn, 
choreograph the expression of downstream IFN-stimulated genes (ISGs) and 
activate several signalling pathways, all of which collaboratively lead to the 
induction of a protective antiviral state and, subsequently, the inhibition of both 
viral replication and proliferation (Stetson and Medzhitov, 2006).  
4.4.2 SARS-CoV ORF6 inhibits interferon production 
To confirm the microarray data, H1299 cells were infected by IBV and 
harvested at 8, 16 and 24 hours post infection. Total RNA was extracted with 
Trizol as previously described and reverse-transcribed into cDNA. Several genes 
involved in the interferon pathways were examined after PCR amplification. Figure 
4.4 shows the coincidence of the reverse-transcription PCR results with the 
microarray data. These results show that ORF6 could inhibit the production of 
interferons during infection.  
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Figure 4.4 RT-PCR results of genes in H1299-WT and H1299-S6 cells 
Cells were infected with IBV at MOI 1. Total RNA was extracted with Trizol 
according to the manufacturer’s instructions at 0, 8, 16 and 24 hours post infection. 
Random primers were used to reverse transcribe RNA into cDNA. PCR was 
carried out with the cDNA as template. Primers of IFN-beta, KLF4, ISGF3G, 
IFIT4 and GAPDH were used to detect the amount of target genes in cDNA. 
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4.4.3 SARS-CoV ORF6 does not prevent IRF3 dimerization 
IRF3 (interferon regulatory factor 3) is known to play key roles to regulate 
the interferon pathway. IRF3 is a member of the interferon regulatory transcription 
factor (IRF) family. IRF3 exists in an inactive cytoplasmic form in normal cells. 
When virus dsRNA are detected, serine/threonine from IRF3 will be 
phosphorylated and form dimerization. IRF3 will form a complex with the cAMP-
response element binding protein (CREB)-binding protein (CREBBP). This 
complex then translocates to the nucleus to activate the transcription of interferons 
alpha and beta, as well as other interferon-induced genes.  
Since IRF3 play key roles in activating the interferon pathway upon virus 
infection, we want to explore whether ORF6 inhibit interferon pathway at these 
steps. H1299-WT and H1299-S6 were first treated with poly:(IC) prior to RNA 
extraction. After poly:(IC) treatment, cells were lysed with a native lysis buffer, 
and IRF3 is detected with native gel electrophoresis. According to Figure 4.1, IRF3 
does not form dimers before induction with poly:(IC). However, 8 hours after 
poly:(IC) treatment, IRF3 dimers were detected in both H1299-WT and H1299-S6 
cells. These dimers were detected at lower amounts compared to that after 16 hours 
of treatment. This decrease may be due to cell loss caused by longer incubation 
with poly:(IC). This result shows that ORF6 does not prevent IRF3 from 
dimerization when the interferon pathway was triggered by poly:(IC) in H1299-
WT cells.  
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4.4.4 SARS-ORF6 prevents the relocation of IRF3 to the nucleus 
We continued to investigate whether the subcellular localization of IRF3 is 
affected by ORF6. Myc-tagged IRF3 were transformed into H1299-WT and 
H1299-S6 cells. These cells were treated with poly:(IC) to trigger the interferon 
pathway as well. The cells were then fixed and permeabilized for 
immunofluorescence staining. Myc antibodies were used to identify the location of 
Myc-tagged IRF3 through observation under confocal microscope. As shown in 
Figure 4.5, IRF3 was concentrated in the cytosol before poly:(IC) treatment in both 
cell lines. As expected, some IRF3 was relocated to the nucleus when H1299-WT 
cells were treated with poly:(IC). However, IRF3 remained in cytoplasm when 
H1299-S6 cells are treated with poly:(IC). This indicated the ability of ORF6 in 
preventing IRF3 from relocating to the nucleus.  
It was reported earlier that ORF6 binds to protein karyopharin alpha 2 
(KPNA2), which functions in the cellular nuclear import. The binding of KPNA2 
by ORF6 blocks the normal nuclear import process. This blockage may prevent the 
transport of IRF3 from cytocol to nuceus, and thus inhibit interferon production 
(Frieman et al., 2007). As such, the binding between ORF6 and KPNA2 may have 
caused the blocking of IRF3 relocation, although more experiments are required for 
better illustration. 
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Figure 4.5 Subcellular localization of IRF3 in H1299-WT and H1299-S6 cells  
H1299-S6, or H1299-WT cells were transfected with p-MycIRF3 using Effectene 
(Qiagen) according to manufacturer’s guideline. For poly:IC treated cells, poly:IC 
was added into the medium 8 hours post transfection. For poly:IC untreated cells, 
no poly:IC was added into the medium. Cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.2% Triton
 
X-100 and washed with PBS. 
Cells were then immune-labeled with antibodies against Myc (left row). The cells 
were washed with PBS and incubated with goat IgG conjugated with Alexa Fluor 
594. DAPI was used to stain nucleus. The cells were mounted with glass cover 
slips using a mounting medium (DAKO). Images were collected with a META 510 
confocal laser-scanning microscope (Zeiss).  
A. Subcellular localization of IRF3 in H1299-S6 cells in response to poly:IC 
treatment. 
B. Subcellular localization of IRF3 in H1299-WT cells in response to poly:IC 
treatment. 
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4.5 SARS-CoV ORF6 inhibits cell death 
4.5.1 Introduction 
The microarray data also illustrated how the transcription of several genes 
in the cell death pathway has been affected in the presence of ORF6 in H1299 
stable cells. STAT1 and BIRC5 are two genes that play important roles in cell 
death. 
4.5.1.1 Functions of STAT1 
As the microarray data have shown, ORF6 interferes with both interferon 
and cell death pathways. STAT proteins are a group of transcription factors, which 
function in a diverse set of signaling cascades initiated by cytokines, growth 
factors, and cellular stress (Simon et al., 1998; Kim and Lee, 2007). There are 
seven STAT proteins identified in this group. STAT1 mediates immune response, 
cell differentiation and cell death (Battle and Frank, 2002; Najjar et al., 2010). 
STAT1 is activated by interferon, interleukins (including IL2 and IL6) and growth 
factors (including EGF, VEGF, FGF) (Subramaniam et al. 2001). STAT1 was 
activated via phosphorylation at tyrosine 701 and serine 727 residues (tyrosine 701 
and serine 727). STAT1 then translocates to the nucleus, where it regulates genes 
involved in inflammation as well as genes linked to cell death. Previous reports 
have shown that some viruses prevent the phosphorylation of STAT1. For 
example, the human metapneumovirus (hMPV) was reported to prevent the 
phosphorylation and nuclear translocation of STAT1, but the mechanism involved 
has not been yet elucidated (Dinwiddie et al. 2008). 
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4.5.1.2 Functions of BIRC5 
BIRC5 is a member in the inhibitors-of apoptosis protein (IAPs) family. It 
promotes cell survival through interference with both caspase-dependent and 
caspase-independent apoptosis. BIRC5 was reported to directly bind to caspase-3 
and caspase-7 (Shin et al., 2001). Through interaction with these caspases, BIRC5 
inhibits caspase-dependent apoptosis. Besides that, BIRC5 was also reported to 
function in caspase-independent apoptosis. BIRC5 interferes with the translocation 
of the apoptosis-inducing-factor (AIF). AIF is a flavoprotein that is normally 
confined to the mitochondrial intermembranal space, but induces chromatin 
condensation and fragmentation of DNA into high molecular weight forms of >50 
kb when it translocates to the nucleus (Cande et al., 2002). Besides interfering with 
both caspase-dependent and -independent apoptosis, BIRC5 also promotes cell 
survival through its interference with cell cycle-related kinases and microtubule 
networks. It has been demonstrated that BIRC5 binds to the Aurora-B kinase, 
Borealin and INCENP to regulation cell division (Jeyaprakash et. al., 2007). It was 
also reported that BIRC5 may also play a role in the regulation of cancer cell 
autophagy (Roca et al., 2008). Taken together, BIRC5 appears to be a master 
molecule that regulates multiple survival pathways in cells.  
4.5.1.3 Cleavage pattern of PARP 
Poly(ADP-ribose) polymerase (PARP) cleavage is widely used as a marker 
of cell death, and different PARP cleavage patterns indicate that cells undergo 
differential apoptosis. PARP is a nuclear enzyme that is activated by DNA strand 
breaks and participates in DNA repair. PARP-1 is also a preferred substrate for 
several 'suicidal' proteases and the proteolytic action of suicidal proteases 
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(caspases, calpains, cathepsins, granzymes and matrix metalloproteinases (MMPs) 
on PARP-1 produces several specific proteolytic cleavage fragments with different 
molecular weights. Caspase-3 and -7 cleave PARP into 24 kD N-terminal fragment 
and 89 kD C-terminal fragments; Calpain-1 cleaves PARP into ~70-40 kD N-
terminal fragments; Cathespsin-B and -D cleaves PARP into 89, 74, 62 kD N-
terminal fragments and 55, 44 kD C-terminal fragments; Cathespsin-G cleaves 
PARP into 74, 62 N-terminal fragments and 55, 44 kD C-terminal fragments; 
Granzyme-A cleaves PARP into 55 kD N-terminal fragment and ~55 kD C-
terminal fragment; Granzyme-B cleaves PARP into 64, 61 kD N-terminal 
fragments and 54, 42 kD C-terminal fragments; MMP-2 cleaves PARP 48 kD and 
66 kD fragment. These PARP-1 signature fragments are recognized biomarkers for 
specific patterns of protease activity in unique cell death programs (Chaitanya et 
al., 2010). 
4.5.2 SARS-CoV ORF6 inhibits staurosporine-triggered cell death in H1299 
cells 
To check the effects of ORF6 on cell death, H1299-WT and H1299-S6 
were treated with staurosporine, an apoptosis inducer, and several methods, 
including FACS, were used to check the rate of apoptosis in these cells.  
Cells were harvested at 4 and 8 hours post addition of staurosporine, 
respectively. The harvested cells were then re-suspended and treated accordingly 
for FACS analysis, and the percentage of dead cells was calculated. As Figure 4.6 
shows, H1299-WT cells had a higher percentage of dead cells than H1299-S6 cells 
when they were treated with staurosporine. When the cells were mock treated, both 
cell types had a low percentage of dead cells. When the cells were treated for 4 
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hours, H1299-WT cells had 25.4% dead cells while H1299-S6 cells had 14.5% 
dead cells. The percentage of dead cells from staurosporine-treated H1299-WT 
cells was significantly higher than that of similarly treated H1299-S6 cells after 8 
hours of treatment as well. 
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Figure 4.6 Cell death in H1299-WT and H1299-S6 cells 
H1299-WT cells and H1299-S6 cells were treated with staurosporine and the cells 
were harvested at 0, 4 and 8 hours post staurosporine treatment. Cells were pelleted 
and washed with pre-chilled PBS before fixing with 70% ethanol and incubation at 
4°C for at least 90 min. The cells were subsequently pelleted and washed with PBS 
twice prior to the addition of 10ug RNase A to each tube. The cells were then 
incubated at room temperature for 5 min prior to the addition of 10ug of propidium 
iodide to each tube, and another round of incubation for 20-30 min in the dark. 
FACS analysis was performed on a BD™ LSR II Flow Cytometer System (BD 
Biosciences). The percentage of dead cells was measured. 
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4.5.3 PARP cleavage pattern is altered in the presence of ORF6 
To study the interference of ORF6 on cell death, the rate of PARP cleavage 
was checked using cell lysates harvested at different time points post virus 
infection. Cell lysates subjected to SDS-PAGE and transferred to a PVDF 
membrane for immunoblotting. As Figure 4.7 shows, the amount of full-length 
PARP (116 kDa) and the 89 kDa cleaved fragment was detected at similar amounts 
in cells infected by both virus types. However, differential cleavage patterns were 
detected when the cells were infected by different virus strains. A band of a size 
around 65kDa was detected at a much higher level at 16 and 24 hours post 
infection when the cells were infected with IBV-S6 than compared to cells infected 
with IBV-luc. Another band, of a size around 40 kDa, also disappeared at different 
time points in cells infected by the two different viruses, respectively. These two 
bands are likely to be cleaved fragments of full length PARP as well. 
4.5.4 STAT1 phosphorylation is inhibited by ORF6 
As the microarray data have shown, ORF6 interferes with both interferon 
and cell death pathways, and STAT1 is a transcription factor that play key roles in 
both. We continued to study whether the presence of ORF6 affects the activation of 
STAT1 when cells were infected by IBV. As shown in Figure 4.7, the total amount 
of STAT1 in cells infected by both IBV strains are at a similar level; however, the 
amount of phosphorylated STAT1 is much lower in cells infected by IBV-S6 than 
that in IBV-luc. Activated pSTAT1 was detected at a much higher-level 16 hours 
post IBV-luc infection, while not much difference was observed in cells infected 
by IBV-S6. Thus, the phosphorylation of STAT1 is inhibited when cells were 
infected by IBV-S6. 
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4.5.5 BIRC5 is up-regulated in the presence of ORF6 
According to the microarray data, BIRC5 is up-regulated at the 
transcriptional level in the presence of ORF6. Therefore, we examined the 
expression of BIRC5 in cells infected by IBV-luc and IBV-S6, respectively. We 
found that the expression level of BIRC5 is much higher in cells infected by IBV-
S6 than in cells infected by IBV-luc (Fig. 4.7). On the other hand, the expression 
level of BIRC5 was too insignificant to be detected 24 hours post infection by IBV-
luc. This observation supports that BIRC5 is up-regulated in the presence of ORF6. 
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Figure 4.7 Expression of proteins in H1299 cells infected with IBV-luc and IBV-
S6 
H1299 cells were infected with IBV-luc and IBV-S6 at MOI 1. The cells were 
incubated with IBV for 1 h, and then fresh medium with FBS was changed to 
maintain cell growth. Cells were harvested 0, 8, 16 and 24 hours post infection. 
Cell lysate was separated with SDS-PAGE. Gels were electroblotted to a PVDF 
membrane, and detected with specific antibodies. Antibodies against PARP, 
STAT1, BIRC5, viral proteins N and ORF6, and tubulin were used for detection of 
the target proteins. 
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4.6 Discussion 
In this chapter, ORF6 was showed to inhibit interferon production, and this 
inhibition may be caused by its interaction with IRF3. ORF6 does not inhibit IRF3 
dimerization, but instead prevents entry of the latter into the nucleus. STAT1 
phosphorylation is affected by ORF6 as well. ORF6 also interferes with the cell 
death pathway, PARP cleavage pattern is altered, and an increase in the expression 
of BIRC5 was observed in the presence of ORF6.  
4.6.1 SARS CoV ORF6 inhibits interferon production.  
Here, we have reported that ORF6 inhibit interferon production when the 
pathway in cells is triggered. IFN expression is a crucial component of the initial 
response of innate immunity, and the inhibition of interferon is a common 
mechanism by which viruses subvert the innate host response. Viral proteins that 
target various aspects of the interferon pathways have been identified. It has been 
reported that SARS-CoV does not result in the production of interferon, and that 
pre-treatment of cells with interferon prevents growth of SARS-CoV (Spiegel et 
al., 2005; Surjit et al., 2004). This inhibition of interferon production may help 
SARS-CoV escape from being eradicated by host immune system. In clinical 
studies, interferon alpha was show to be an effective medicine to control SARS-
CoV replication in the early stages of infection (Loutfy et al., 2003). Patients 
treated with interferon alpha have obvious better outcome than patients treated with 
other methods (Zhao et al., 2003). Interferon effectively inhibits SARS-CoV 
replication in mouse models. SARS-CoV can replicate well in STAT1 knockout 
mouse, and lead to prolonged viremia, extensive lung pathology, and spread to 
multiple organs (Hogan et al., 2004).  
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Interferons can effectively inhibit SARS-CoV replication, but SARS-CoV 
has developed mechanisms to prevent interferon production in patients. While 
SARS-CoV ORF6 is one of the proteins that carry out this function, it is not the 
only viral protein that inhibits interferon production. The Nucleocapsid protein, 
ORF 3b, Nsp1 and Nsp3 were also reported to function as interferon antagonists 
(Narayanan et al., 2008; Wathelet et al., 2007; Zust et al., 2007; Ye et al., 2007; 
Kopecky-Bromberg et al., 2006). 
SARS-CoV ORF6 also prevents the re-localization of IRF3 from cytosol to 
nucleus. When H1299-S6 cells were treated with poly:(IC), IRF3 still forms dimers 
but fails to be transported into nucleus. On the other hand, ORF6 may prevent IRF3 
transport via other nuclear import protein. It has been reported earlier on that ORF6 
binds to the cellular nuclear import protein KPNA2, and the binding between 
KPNA2 and ORF6 inhibits the normal nuclear import process (Frieman et al., 
2007).  The block of nuclear import process may be responsible for the subcellular 
localization of IRF3, which impairs the interferon pathway. As a result of lower 
interferon production, phosphorylation of STAT1 is inhibited when H1299 cells 
were infected by IBV-S6. 
4.6.2 SARS-CoV ORF6 interferes with cell death 
Differential PARP cleavage patterns were detected in cells infected by IBV-
luc or IBV-S6. The amount of the 60 kDa cleavage fragment was drastically 
different in cells infected by IBV-luc, or by IBV-S6, respectively. As summarized, 
several proteases in the cell death pathway may cleave PARP to get cleavage 
fragments of this size. Calpain-1 cleaves PARP into 70 and 40 kDa N-terminal 
fragments; MMP-2 cleaves PARP1 into 48 kDa and 66 kDa fragments; other 
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proteases including Cathespsin-B and -D, Cathespsin-G and Granzyme-B also 
cleave PARP into fragments of around 60 kDa (Chaitanya et al., 2010). In this 
study, we are unable to tell the exact size of this band due to the limitations of 
SDS-PAGE. In general, however, this band is a marker for cell death. Thus, these 
results suggest that ORF6 interferes with the cell death pathway. 
The amount of BIRC5 is higher in the presence of ORF6 when H1299 cells 
were challenged with IBV virus. BIRC5 is a member of IAP family of proteins, 
and is also named Survivin. As its name indicates, BIRC5 promotes cell survival. 
BIRC5 inhibits cell death via co-operative interactions with other partners, like 
XIAP, in vivo (Dohi et al., 2004). XIAP then directly binds caspases with high 
affinity to shut off their cell killing ability (Huang et al., 2001). The higher 
expression level of BIRC5 obtained here suggested that ORF6 might also interfere 
with cell death in this way. The microarray data of other genes in apoptosis 
pathway also support that ORF6 inhibits cell death.  
However, over-expression of SARS-CoV ORF6 was reported to increase 
virus-induced apoptosis in Cos7 and Vero cells (Ye et al., 2008). Differential 
expression levels of ORF6 may have caused these inconsistent results, as the virus 
itself was used to express ORF6, and the protein expression level obtained seemed 
to be significantly lower than that in previous reports. The functions of ORF6 in 
cell death need to be further explored. 
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CHAPTER 5. DISCUSSION AND  
FUTURE WORKS 
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5.1 SARS-CoV ORF9b vs. I proteins from other coronaviruses 
ORF9b was illustrated to undergo translation via ribosomal leaky scanning, 
after the introduction of mutations to the context of the translation initiation sites.  
When co-expressed with SARS CoV M and E proteins, ORF9b was incorporated 
into virion like particles. Co-expression of M and ORF9b leads to successful VLP 
formation and release. The pull-down assays also demonstrated the interaction of 
ORF9b with SARS CoV structural proteins E and M.  
Protein 9b is incorporated into the SARS-CoV virion-like-particles. This 
observation coincides with the previous report that I protein of MHV is also 
detected in coronavirus virions (Fischer et al., 1997). Till now, accessory proteins 
ORF3a (Shen et al., 2006) ORF7a (Huang et al., 2006) and ORF7b (Schaecher et 
al., 2007) have been identified as structural proteins. In the analysis of intra-viral 
protein-protein interactions of the SARS coronavirus ORFeome using a Yeast-two-
hybrid (Y2H) matrix screen method, 9b also interacts other SARS-CoV proteins 
including NSP3, NSP5, NSP7, NSP8, NSP10, NSP12, NSP13, NSP14, NSP15, 
protein 8a and protein 8b (Brunn et al., 2007). It has been well illustrated that these 
NSPs mainly function on transcription and translation during the early stages of 
virus replication. Extensive interaction between 9b and nonstructural proteins also 
suggest that 9b may play roles in the early stage of virus replication as well.  
In this study, we have identified one more protein, ORF9b, as a structural 
protein. In comparison with other coronaviruses, SARS-CoV incorporates more 
proteins into virions, and these proteins may have function in virus-host 
interactions. Previous reports have also shown that ORF6 and ORF3a interfere with 
both the interferon and apoptosis pathways (Kopecky-Bromberg et al., 2006; Tan 
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et al., 2004). Thus, these accessory proteins may help the virus escape from host 
immune responses in the early infection stages such that the virus could replicate 
more efficiently in the host. If the latter were true, these proteins may play crucial 
roles in the viral pathogenesis. Here, only the functions of ORF9b in virus 
replication have been studied. Whether or not ORF9b also interacts with host 
pathways remains to be further investigated. 
The exact function of coronavirus I ORFs and their proteins is not known 
except for MHV I protein, which is a constituent of the virion (Fischer et al., 1997). 
In MHV, the I protein can contribute to plaque morphology too (Fischer et al., 
1997). The BCV I protein is only suggested to be part of the virion (Senanayake et 
al., 1992). The PEDV I protein was not present in detectable amounts in virions 
(Singh, 1999). While the functions of I proteins from other coronaviruses are still 
not clear, we show here that protein 9b is present in virion-like particles and 
mediates the virion assembly and release. This mediation may be carried out via its 
interaction with E and M.  
While 9b protein does not share a similar sequence as I proteins from other 
coronaviruses, it does share some features with other I proteins. They are all hidden 
in N gene, which is the shortest mRNA from the coronaviruses. The protein 
synthesis follows ribosomal leaky scanning, and it has been suggested that the I 
protein can be incorporated into virions. This I protein is conserved in all group II 
coronaviruses (Fischer et al., 1997, Lapps et al., 1987 and Senanayake and Brian, 
1997).  
Our studies on 9b imply that I proteins may also function during virion 
assembly. If this hypothesis were true, it would explain why E is essential in some 
  153 
coronaviruses, including SARS-CoV and MHV, and is dispensable in others, 
including TGEV and IBV (Curtis et al., 2002, Ortego, 2002; DX Liu, unpublished 
observations; Kuo et al., 2003; DeDiego, 2007). It is known that the major function 
of E protein is to facilitate the virion assembly (Liu et al., 2007). If 9b and other I 
protein have similar functions like E during virion assembly, E could be deleted 
with no obvious harm to SARS replication. To our knowledge, all the reported 
coronaviruses (MHV; SARS-CoV) that can replicate without E have ORF I within 
N, whereas coronaviruses that are dependent on E (i.e. TGEV, IBV) have no ORF I 
within N. The functions during assembly process of I proteins from other 
coronaviruses will therefore need to be further examined.  
5.2 Lipid rafts and coronavirus assembly 
We also found that lipid rafts are required by coronaviruses for efficient 
VLP assembly and release, and knock down of Snapin leads to obvious lower 
replication efficiency of IBV in H1299 cells. As described earlier, Snapin is a 
component of the SNARE complex of proteins, which functions in synaptic vesicle 
docking and fusion (Ilardi et al., 1999). Snapin is also a component of the 
biogenesis of lysosome-related organelles complex 1 (BLOC1), which is required 
for biogenesis of the endosomal-lysosomal system (Starcevic and Dell'Angelica, 
2004). Snapin knocked-out cells exhibit accumulation of immature lysosomes. The 
knock-out of Snapin impairs retrograde transport of late endosomes along 
processes, reduces lysosomal proteolysis due to impaired delivery of internalized 
proteins and hydrolase precursors from late endosomes to lysosomes, and affects 
clearance of autolysosomes (Cai et al., 2010).  
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In general, Snapin is critical for the onset of efficient autophagy. A number 
of viruses with RNA genomes have been reported to induce autophagy-like events 
and/or or require the formation of autophagosome-like structures in vitro; however, 
further investigation will be required to more precisely define the roles of 
autophagy proteins, double-membrane vesicles, and the classical autophagy 
pathway in these infections. Although autophagy is normally considered to play 
anti-viral functions as part of innate immunity, it is also reported to facilitate virion 
egress for several viruses, including HIV1, Dengue virus and Influnza A virus 
(Kyei et al., 2009; Espert et al., 2006; Denizot et al., 2008; Zhou et al., 2009). 
Autophagy increases the replication efficiency of these viruses. Autophagosomes 
may also serve to target newly formed HIV virions to multi-vesicular bodies that 
are believed to mediate the release of HIV (Carter et al., 2008). In conclusion, 
some viruses may hijack autophagy for replication, morphogenesis or release. The 
impaired replication efficiency of IBV observed in Snapin knockdown cells may 
thus be caused by impaired autophagy in these cells. 
5.3 SARS-CoV ORF6 and virus pathogenesis 
 Compared with other human coronaviruses, which cause common cold, 
SARS-CoV has more severe pathogenesis mainly due to its wide distribution in 
different organs, and its interaction with the human immune system. Examination 
on autopsies of SARS patients showed that SARS is a systemic disease with viral 
shedding in respiratory secretions, stools, urine, and even sweat (Ding et al., 2004; 
Farcas et al., 2005). SARS-CoV Spike protein is responsible for the tropism, as it 
binds to ACE2 receptor and mediates virus entry. SARS-CoV has mechanisms to 
counter the host immune responses, thus causes high pathogenesis and mortality. 
Microarray results of PBMCs from 10 SARS patients, compared with healthy 
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controls, suggest that the patient responses to SARS are mainly innate 
inflammatory responses, and no significant upregulation of interferons were 
detected (Reghunathan et al., 2005).  In this study, it was demonstrated that SARS-
CoV ORF6 inhibits interferon production. Together with other interferon 
antagonists, ORF6 contributes to the high pathogenesis of SARS-CoV.  
 SARS-CoV ORF6 was shown to inhibit cell death when H1299-S6 cells 
were challenged with staurosporine. The expression level of BIRC5, which 
promotes cell survival, is higher in H1299-S6 cells as well. However, previous 
reports have demonstrated that ORF6 induces apoptosis (Ye et al., 2008). The 
reason for this inconsistence is still not clear. Cell line with stable ORF6 expression 
is used in our study, while cells with transient expression were used in their study. 
The expression level of ORF6 may be different, and transfection reagents may 
stress cells. The interaction between ORF6 and apoptosis need to be further 
explored. 
Analysis of the microarray data has also shown that, other than the genes in 
the interferon pathway and in cell death, genes in other function groups are also 
significantly changed in cells with stable ORF6 expression. Amount of genes with 
functions in cellular growth and proliferation were identified. Genes responsible 
for functions including tissue morphology, molecular transport, nucleic acid 
metabolism, antigen presentation, immune cell trafficking and amino acid 
metabolism, were also modified in H1299-S6 cells. Previous microarray data 
reported by other groups also detected some of the genes (Zhang et al., 2004; 
Leong et al., 2005; Frieman et al., 2008). The interference of SARS-CoV ORF6 
with these functional groups needs to be further studied.  
All these functions of SARS-CoV ORF6 may contribute to the high 
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pathogenesis of SARS-CoV. In previous reports, the pathogenesis of MHV was 
significantly enhanced when SARS-CoV ORF6 was inserted into MHV genome 
(Tangudu et al., 2007). All these data suggest that SARS-CoV ORF6 plays roles in 
virus pathogenesis through its interaction with host pathways. 
5.4 Potential applications 
5.4.1 Virion like particles are promising vaccine candidates 
Virion-like particles of SARS-CoV were produced in our study. The VLPs 
were produced from mammalian cells after the transfection of SARS-CoV 
structural proteins. According to previous studies, these VLPs have the same 
morphology as viruses, and major antigens including M, N and E are present in the 
VLPs (Mortola and Roy 2004; Siu, Teoh et al., 2008; Roldao, Mellado et al., 
2010). At the same time, VLPs do not have genomic RNA inside the particles, and 
so are not able to replicate themselves after they are delivered into human bodies.  
These characters make VLPs promising candidates as ideal vaccines. Safety 
and efficiency have been two major concerns in vaccine development. VLPs 
incorporate key viral immunologic features, including particulate structures, major 
antigens and induction of innate immunity activation. These characteristics make 
VLPs highly effective inducers of potent B- and T-cell responses. They carry no 
replicative genetic information and cannot replicate; thus, no mutant strain or 
recombinant strain will appear after they are delivered into human body. In short, 
they are safe and effective vaccine candidates. Compared with other types of 
vaccines, including live attenuated viruses, inactivated viruses, recombinant viruses 
and subunit vaccines, VLPs have these inherited advantages on efficiency and 
safety. 
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In recent years, several VLP based vaccines were approved. 
GlaxoSmithKline developed VLP based vaccines for hepatitis B virus (Engerix) 
and human papillomavirus (Cervarix); Merck developed VLP based vaccines for 
hepatitis B virus (Recombivax) and human papillomavirus (Gardasil). There are 
more VLP-based vaccine candidates in stages of clinical. The target viruses include 
influenza virus, parvovirus, Norwalk and various chimeric VLPs. Much more VLP 
based candidates are at the stage of fundamental research, although they have 
showed promising results in preclinical tests (Roldao, Mellado et al., 2010). 
The development of vaccines against SARS-CoV was hindered due to 
several reasons. Inactivated vaccines, viral and bacterial vector vaccines, 
recombinant protein vaccines, subunit vaccines, DNA vaccines, and live-attenuated 
virus vaccines have been studied in different animal models (Subbarao and Gillim-
Ross 2006; Lin, Zhang et al., 2007; Enjuanes, Dediego et al., 2008). Although 
different animal models are used in vaccine studies, the most appropriate model for 
studying SARS is the ferret, since it develops the typical clinical signs, viral 
replication patterns and lung pathology compatible with that of SARS pathogenesis 
in humans. While there is much evidence that various vaccine strategies against 
SARS are safe and immunogenic, vaccinated animals still display significant 
disease upon challenge. Moreover, potential vaccine enhancement of SARS have 
also been shown in some studies (Ruh, 2010). 
More work will need to be done to develop VLPs of SARS-CoV into 
vaccines. Firstly, spike proteins should be included in VLPs. Spike protein was co-
expressed to form VLPs in our study. This is to simplify the VLP system, and to 
facilitate our study. Spike protein does not play key roles in virus assembly, but it 
is a major antigen during infection. S protein is also responsible for the binding of 
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SARS-CoV to host cellular receptor and it determines the tissue distribution of 
viruses (Wong et al., 2004; Hofmann and Pohlmann, 2004). Therefore, it is 
important in include spike protein in VLPs to enhance the effectiveness as vaccine. 
Secondly, the production efficiency of VLPs needs to be improved. Currently, 
plasmids responsible structural proteins are transfected into cells at simultaneously. 
The production of VLPs is not very high due to massive cell death caused by 
transfection reagents. Cell lines that stably express structural proteins may be used 
for VLP production in the future. Moreover, suspension cells should be used for 
larger scale production. 
5.4.2 Reverse genetic engineering of IBV can be a platform for gene delivery 
and vaccine development 
With the reverse genetic approach, the IBV genome was modified. 
Luciferase and SARS-CoV ORF6, respectively, were inserted into IBV genome in 
our study. These recombinant virus strains are stable when they are passaged in 
Vero cells. Other studies also reveals that IBV could be used as vector to delivery 
set of genes, including GFP, SARS-CoV 8b and 8ab, SARS-CoV S, eukaryotic 
translation initiation factor 3f (eIF3f), and dengue core gene (Le, Wong et al., 
2007; Shen, Fang et al., 2009). The genetic stability of recombinant IBV carrying 
foreign genes was studied. The stability is related to the size and functions of 
foreign genes, and the locations of foreign genes in IBV genome (Shen, Fang et al., 
2009). 
IBV has several attractive traits as a potential gene delivery system. Firstly, 
it is safe, because it replicates in the cytoplasm of the infected cells and has no 
DNA stage, which ensures that viral sequences are unlikely to be integrated into 
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the host genome. Secondly, the clongng capacity could be more than 6kb, because 
coronavirus has the largest genome among all RNA viruses, and genome size of 
IBV is around 27kb (Enjuanes, Sola et al., 2005). Thirdly, foreign genes be 
expressed easily in IBV. The unique transcription process involving transcription 
of a nested set of 6–8 subgenomic mRNA species. Foreign genes will be expressed  
by adding TRS a head of the genes in the virus genome. Successful results include 
SARS-CoV (Sims et al., 2005), MHV (Fischer et al., 1998), and IBV (Le et al., 
2007 and Youn et al., 2005). Also, tropism of coronavirus could be managed 
readily because the virus entry process has been well studied. The interaction 
between viral Spike protein and specific cell receptors plays key roles in virus 
attachment. The tropism of coronavirus can be modified by the modification of the 
S genes (Casais et al., 2003 and Sanchez et al., 1999). This feature enables 
researcher to design viruses target specific cells, tissues and hosts. Lastly, multiple 
foreign genes can be expressed. HIV-1 genes were cloned into coronavirus and 
successfully expressed (Thiel et al., 2003 and Eriksson et al., 2006). Also, 
coronaviruses infect host through the mucosal route, which makes it convenient for 
gene delivery.  
All these features support IBV to be a promising platform for gene delivery 
vectors and multivalent vaccines. 
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